
==== Front
Transl Psychiatry
Transl Psychiatry
Translational Psychiatry
2158-3188
Nature Publishing Group UK London

39256358
3075
10.1038/s41398-024-03075-8
Article
MicroRNAs: pioneering regulators in Alzheimer’s disease pathogenesis, diagnosis, and therapy
Li Yao-Bo 1
Fu Qiang 2
Guo Mei 3
Du Yang 2
Chen Yuewen yw.chen1@siat.ac.cn

45
http://orcid.org/0000-0002-7529-4408
Cheng Yong yongcheng@muc.edu.cn

123
1 https://ror.org/0044e2g62 grid.411077.4 0000 0004 0369 0529 Center on Translational Neuroscience, College of Life and Environmental Sciences, Minzu University of China, Beijing, China
2 https://ror.org/0044e2g62 grid.411077.4 0000 0004 0369 0529 Institute of National Security, Minzu University of China, Beijing, China
3 https://ror.org/0044e2g62 grid.411077.4 0000 0004 0369 0529 Key Laboratory of Ethnomedicine of Ministry of Education, School of Pharmacy, Minzu University of China, Beijing, China
4 grid.9227.e 0000000119573309 Chinese Academy of Sciences Key Laboratory of Brain Connectome and Manipulation, Shenzhen Key Laboratory of Translational Research for Brain Diseases, The Brain Cognition and Brain Disease Institute, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen–Hong Kong Institute of Brain Science—Shenzhen Fundamental Research Institutions, Shenzhen, China
5 https://ror.org/00sz56h79 grid.495521.e Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development, HKUST Shenzhen Research Institute, Shenzhen, China
10 9 2024
10 9 2024
2024
14 36721 2 2024
21 8 2024
27 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
This article delves into Alzheimer’s disease (AD), a prevalent neurodegenerative condition primarily affecting the elderly. It is characterized by progressive memory and cognitive impairments, severely disrupting daily life. Recent research highlights the potential involvement of microRNAs in the pathogenesis of AD. MicroRNAs (MiRNAs), short non-coding RNAs comprising 20–24 nucleotides, significantly influence gene regulation by hindering translation or promoting degradation of target genes. This review explores the role of specific miRNAs in AD progression, focusing on their impact on β-amyloid (Aβ) peptide accumulation, intracellular aggregation of hyperphosphorylated tau proteins, mitochondrial dysfunction, neuroinflammation, oxidative stress, and the expression of the APOE4 gene. Our insights contribute to understanding AD’s pathology, offering new avenues for identifying diagnostic markers and developing novel therapeutic targets.

Subject terms

Neuroscience
Diagnostic markers
https://doi.org/10.13039/501100001809 National Natural Science Foundation of China (National Science Foundation of China) 82071676 82071676 82071676 82071676 Li Yao-Bo Fu Qiang Guo Mei Cheng Yong 国家自然科学基金委员会与研究资助局联合科研资助计划 （32061160472）NSFC-RGC Joint Research Scheme (32061160472)issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Alzheimer’s disease (AD): an overview

AD stands as a leading neurodegenerative disorder, predominantly seen in the elderly. Characterized by early-stage subtle memory lapses and declines in verbal fluency, AD is a major contributor to dementia, accounting for 50–75% of all cases [1]. In 2010, ~35.6 million individuals suffered from dementia globally, with projections suggesting a dramatic rise to 135 million by 2050 [1, 2]. In the United States alone, an estimated 6.7 million elderly individuals currently live with Alzheimer’s dementia, a number expected to double by 2060 in the absence of medical advancements. Notably, AD has become a significant cause of death, ranking as the sixth leading cause in the U.S. as of 2019 10.1002/alz.13016. While deaths from other conditions like heart disease and HIV have declined, Alzheimer’s-related fatalities have surged by over 145% since 200010.1002/alz.12638.

The pathological hallmark of AD is neuronal death and synaptic loss, culminating in severe cognitive dysfunction. Key neuropathological indicators include extracellular β-amyloid (Aβ) accumulation and intracellular accumulation of phosphorylated tau, leading to neurofibrillary tangles (NFTs) [3, 4]. Diagnosis and assessment of AD severity rely on memory and physical evaluations [5], with a definitive diagnosis possible only post-mortem through autopsy findings correlating Aβ deposition with clinical symptoms [6]. The challenge of diagnosing Mild Cognitive Impairment (MCI) at early stages, a potential precursor to AD, underscores the need for reliable biomarkers [7, 8]. MicroRNAs (MiRNAs) have emerged as pivotal biomarkers, playing crucial roles in AD’s progression [9–12]. Differentially expressed miRNAs have the potential to be used as biomarkers for diagnosing and monitoring AD progression. These miRNAs regulate several biological functions, with the most significant and important biological processes and pathways related mainly to the maintenance of genomic integrity, proteostasis control, regulation of apoptotic processes, and neurotrophic support [13]. This review examines the changes in miRNA expression and their consequent effects on neuronal dynamics in the AD brain, discussing their significance in advancing our understanding of the disease’s progression and potential preventative strategies.

Molecular changes and pathogenesis of AD

In AD, the brain undergoes significant structural alterations, including a drastic reduction in neuronal count, the formation of NFTs composed of hyperphosphorylated tau, and the development of Aβ or senile plaques [14, 15]. These plaques, characterized by protein deposits outside cells encircled by dystrophic neurites, predominantly consist of Aβ, stemming from aberrant metabolism of the β-amyloid precursor protein (APP). APP, a transmembrane protein, typically undergoes enzymatic cleavage to produce soluble α-APP and β-APP [16–18]. However, in AD patients, this metabolic pathway malfunctions, leading to the accumulation of Aβ, a process central to the pathogenesis of AD [19, 20]. These deposits incite inflammatory responses and oxidative stress, culminating in neuronal damage and death [21–23].

In addition to Aβ deposition, the aberrant aggregation of tau protein is a crucial aspect of AD pathogenesis. Normally, tau protein, a microtubule-associated protein, maintains neuronal structural stability [24]. In AD, however, tau undergoes abnormal phosphorylation and aggregation, resulting in the formation of NFTs [25, 26]. The exact mechanisms behind tau aggregation remain partially understood, but key hypotheses include aberrant phosphorylation and splice mutation of the tau protein. Hyperphosphorylation leads to tau proteins aggregating into fibrillary tangles, while splice mutations can alter tau protein structure, promoting aggregation [27]. These tangles accumulate inside brain neurons, forming NFTs that disrupt normal nutrient transport and signal transmission within neurons, leading to neuronal dysfunction and death [28].

AD manifests in two primary forms: early-onset Alzheimer’s disease (EOAD) and late-onset Alzheimer’s disease (LOAD) [29]. EOAD, typically occurring in individuals under 65, is a rarer genetic variant of AD. LOAD, on the other hand, is the more common form of dementia in individuals over 65 and is characterized by sporadic AD attributed to abnormal amyloid mechanisms [30]. Both EOAD and LOAD exhibit distinct memory impairments, with EOAD often presenting with nonamnestic features and LOAD patients showing increasing semantic memory disorders. These differences underscore the necessity for tailored approaches in understanding and treating each AD type [31–33].

Genetic research has pinpointed four genes implicated in autosomal dominant or EOAD: APP, presenilin 1 (PS1), presenilin 2 (PS2), and apolipoprotein E (APOE). The formation of amyloid plaques, primarily composed of Aβ peptides, is significantly influenced by mutations within these genes [19, 34, 35]. Specifically, mutations in APP and presenilin proteins are known to elevate the production of Aβ peptides, especially the more amyloidogenic Aβ42, which is closely linked to the development of amyloid plaques in the brain. This evidence positions the presenilin proteins as initial factors in the cascade leading to Aβ42 accumulation and plaque formation [36, 37]. APOE, a key player in lipid transport, is encoded by genes on chromosome 19 and plays a protective role against AD. Present in brain cells like oligodendrocytes, astrocytes, and microglia [35]. APOE comes in three isoforms: E2, E3, and E4, with varying frequencies in the population [38]. Interaction between APOE and Aβ peptides suggests a complex relationship where APOE binds to Aβ, potentially mitigating the formation of disease-associated fibrils [39, 40]. APOE3, for instance, is thought to shield neurons from Aβ‘s detrimental effects by facilitating its clearance [41]. In contrast, the APOE4 variant is linked to increased risks of coronary and cerebrovascular diseases, which are significant risk factors for AD [42–44].

Beyond genetic predispositions, environmental factors play a critical role in AD’s pathogenesis. Incidences of head trauma with loss of consciousness have been correlated with a higher prevalence of AD [45]. Aging remains the most significant risk factor, with the disease’s incidence rising as the population ages [46, 47]. Lifestyle choices, including poor diet, lack of physical activity, and exposure to pollutants [48–51], alongside cardiovascular conditions like diabetes [52–54], hyperlipidemia, and hypertension [55–57], have been associated with an increased risk of AD. Additionally, long-term exposure to toxic substances, such as pesticides and heavy metals, may elevate AD risk [58–60]. The aging process itself, marked by a decline in cellular function and repair capacity, contributes to AD development [61]. However, it’s crucial to note that while these environmental factors are linked to AD, they do not guarantee its onset [62, 63]. The complexity of AD’s pathogenesis, with many aspects still unknown, underscores the need for further research.

In summary, AD is a multifactorial disorder influenced by abnormal metabolism of β-APP, Aβ deposition, tau protein aggregation, genetic mutations, environmental factors, and the aging process. Understanding the molecular biology underlying AD is vital for unveiling its pathology and identifying therapeutic targets. Despite the availability of symptomatic treatments, a cure for AD remains elusive, highlighting the urgency for continued in-depth research [9–11]. Recent insights into the role of miRNAs in AD offer promising directions for unraveling its pathological processes and developing novel therapeutic strategies.

MiRNAs: regulatory functions and implications in AD

MiRNAs are a class of small, non-coding RNA molecules, ranging in length from 20 to 24 nucleotides, that play a pivotal role in the regulation of gene expression within eukaryotic cells. These molecules achieve regulation by binding to the messenger RNA (mRNA) of target genes, affecting both transcriptional and translational processes [64]. MiRNAs are integral to a myriad of cellular functions, including cell proliferation, differentiation, apoptosis, metabolism, and immune response. The biosynthesis of miRNAs involves several key steps. Initially, miRNA genes are transcribed in the nucleus into primary miRNA transcripts (pri-miRNAs), which can extend to hundreds of nucleotides in length [65]. These pri-miRNAs are then processed by the Drosha enzyme and its cofactor into precursor miRNA (pre-miRNA) fragments, ~70 nucleotides long [64, 66]. Subsequently, pre-miRNAs are transported to the cytoplasm [67], where they are further cleaved by the RNAse III enzyme Dicer and the TAR RNA-binding protein (TRBP) into miRNA duplexes. A helicase unwinds these duplexes, resulting in a single-stranded mature miRNA and the degradation of the complementary strand [68]. Mature miRNAs are then incorporated into the RNA-induced silencing complex (RISC), forming active RISC-miRNA complexes that modulate gene expression by interacting with target mRNAs [69] (Fig. 1). MiRNAs regulate gene expression through two primary mechanisms: by binding completely to the 3′ untranslated region (3′ UTR) of target mRNAs, leading to mRNA degradation and gene expression inhibition, or by partially binding to the 3′ UTR to repress the translation process, thereby reducing gene expression [70, 71]. Interestingly, some miRNAs can also bind to the 5′ UTR or coding sequences of mRNAs, in some cases even enhancing translation [72].Fig. 1 MiRNAs biogenesis.

The microRNA (miRNA) biosynthesis pathway is categorized into classical and non-classical. (1) In the classical pathway, miRNA genes are transcribed to generate primary miRNAs (pri-miRNAs), which are processed by Drosha and DGCR8 to form precursor miRNAs (pre-miRNAs), and then transferred to the cytoplasm where Dicer generates double-stranded miRNAs, which ultimately bind to RISC to regulate the translation of target mRNAs; (2) the non-classical pathway directly generates double-stranded miRNA. [miRNA microRNA, Pri-miRNA primary microRNA), Pre-miRNA precursor microRNA, RISC RNA-induced silencing complex, mRNA (messenger RNA, ORF open reading frame, Ago Argonaute, DGCR8 DiGeorge Syndrome Critical Region 8, Dicer Dicer enzyme].

A collection of 3028 genes associated with the cell cycle identified in a 2016 study [73], represents a wide array of protein classes. These include nucleic acid binding proteins (594), transcription factors (305), cytoskeletal proteins (232), kinases (174), phosphatases (111), and chaperones (84). Within this set, 2125 genes have been validated as targets of 424 miRNAs, with miR-335 alone targeting 301 genes. This highlights the significant role of miRNAs in post-transcriptional regulation, where individual miRNAs can influence the expression of numerous mRNAs [74]. This capability makes miRNAs promising therapeutic targets for complex diseases, such as brain disorders, due to their ability to regulate multiple genes simultaneously.

MiRNAs have been implicated in the pathogenesis of various diseases, including cancer [75], cardiovascular diseases [76], and neurological disorders like AD [77]. In the context of cancer, aberrant miRNA expression is closely associated with tumor initiation, progression, and metastasis. In cardiovascular diseases, miRNAs regulate processes such as cardiac myocyte proliferation and apoptosis, affecting heart structure and function [78–84]. Specifically, in AD, alterations in miRNA expression levels have been linked to key pathological features [85], including tau protein phosphorylation and aggregation, mitochondrial dysfunction, and Aβ peptide production (Table 1). These changes in miRNA activity contribute to neuronal dysfunction and cell death, playing a critical role in the disease’s progression. The study of miRNAs in AD offers insights into the molecular mechanisms underlying the disease and highlights the potential of miRNAs as biomarkers for diagnosis and targets for therapeutic intervention [86, 87].Table 1 MiRNA expression and the pathways involved in AD progression.

Type of pathway	MiRNAs	Expression changes in AD patients	Intermediate target	Relevance to final goal (±)	Biological specimen/animal models	Ref.	
BACE1	miR-149	↓		–	SH-SY5Y	[102]	
miR-374b-5p	↓		–	SH-SY5Y, BV2	[101]	
miR-124	↓		–	SH-SY5Y	[103]	
miR-15b	↓		–	SH-SY5Y	[104]	
miR-16	↓		–	PC12/N2a	[105]	
miR-34a-5p	↓		–	MCN,N2a	[106]	
miR-125b-5p	↓		–	MCN,N2a	[106]	
miR-22-3p	↓	MAPK14	–	APPswe/PSΔE9/N2a	[109]	
miR-340			–	SAMP8 mice	[108]	
miR-195	↓		–	HEK293/N2a/APP	[111]	
miR-186			–	N2a,7PA2	[112]	
APP	miR-106a			–	HEK293	[113]	
MiR-520c			–	HEK293	[113]	
miR-20a			–	HeLa,N2A and SK-N-SH	[99]	
miR-16			–	SAMP8 mice	[114]	
Aβ	miR-128	↑	Cathepsin B, D,S, β-Galactosidase,α-Mannosidase,β-Hexosaminidase	–	AD patient peripheral blood	[116]	
p-Tau	miR-132	↑	GTDC-1	+	HEK293	[125]	
miR-425-5p	↑	HSPB8	+	HEK293/tau	[126]	
miR-124-3p	↓	Caveolin-1-PI3K/Akt/GSK3β	–	N2a/APP695swe	[127]	
miR-512	↓	cFLIP, MCL1	–	Human Alzheimer brain sections	[128]	
miR-483-5p	↑	ERK1/2	–	HEK293	[129]	
miR-125b-5p		PME-1	–	HEK293, N2a	[130]	
miR-146a	↓	Nkd2	–	B6/JNju-Tg (APP/PS1), HMC3, SH-SY5Y	[160]	
Neuroinflammation	miR-132	↓	NF-KB,p38MAPK	–	PC-12	[163]	
miR-155	↓	SOCS1, STAT5, IFN-γ	–	3xTg-AD mice	[166]	
miR-107	↓	BACE1	–	SH-SY5Y, HEK293, C57BL/6J (APP/PS1) mice	[175]	
oxidative stress	miR-125b	↑	SPHK1	+	N2a APPSwe/Δ9	[176]	
miR-125b	↑	NCAM/GSK3β	+	PC12	[177]	
miR-146a	↑	CFH/NF-KB, ROCK1/PTEN, SOD2	+	PC12,HN,5xFAD mice	[178–180]	
miR-200c	↑	ER stress, S6K1	–	APPswe/PSΔE9 mice, SH-SY5Y	[182, 183]	
miR-743a	↓	MDH2	–	HT22	[210]	
Mitochondrion	miR-34a	↑	NFKB、STAT1	–	3xTg-AD mice	[214]	
miR-195		MFN2	–	SAMP8 mice	[216]	
miR-455-3p	↑	AβPP	–	MN	[219]	
miR-23a	↓	sirt1	+	aMCI	[221]	
miR-195		PIP2/Aβ/p-Tau	–	Primary cortical neurons(APOE3, APOE4)/APOE4+/+KI mice	[235]	
APOE4	miR-203		Caspase3/Bcl2/p-Tau	–	C57/BL6 mice(TBI)	[236]	

In conclusion, miRNAs are crucial regulators of gene expression, influencing a wide array of biological processes and disease pathologies. The aberrant expression of miRNAs is intricately linked to the development and progression of diseases, including AD. Understanding the role and mechanisms of miRNAs in the brain and their impact on disease progression is essential for developing novel diagnostic and therapeutic strategies, particularly in the context of neurodegenerative diseases like AD.

Regulation of Aβ by MiRNAs in AD

The hallmark complications of AD, such as memory impairment and cognitive decline, are closely associated with changes in synaptic plasticity [88]. One of the important characteristics of AD patients is the alteration in synaptic plasticity, which affects the brain’s ability to adapt and process information [89]. Genome-wide transcriptome studies have revealed that many key genes involved in synaptic activity are downregulated in AD [90, 91]. These miRNAs are implicated in the formation of senile plaques and NFTs, with extracellular amyloid plaques as the most notable feature. Postmortem analyses of AD patients reveal axonal and dendritic deformations and synaptic disruption in hippocampal and neocortical areas surrounding amyloid deposits [92]. The accumulation of Aβ peptides, a byproduct of the APP processed by BACE1, plays a crucial role in neuronal cytotoxicity, representing a key pathogenic factor in AD [93].

Evidence increasingly supports the role of miRNAs in modulating Aβ production. APP, a large transmembrane glycoprotein [94], undergoes cleavage by β-secretases and γ-secretases to produce Aβ, marking the amyloidogenic pathway. Alternatively, the non-amyloidogenic pathway involves α-secretase cleaving APP, preventing Aβ peptide formation [95]. Disruption in the balance between Aβ production and clearance leads to extracellular Aβ accumulation, neurofibrillary tangle formation, neuronal degeneration, and loss of function [96]. The expression levels of Aβ are intricately linked to those of APP and BACE1. Mutations in presenilin-1, a component of the γ-secretase complex involved in Aβ production, along with deficiencies in presenilin, inactive mutants, γ-secretase inhibitors, and loss of β-APP or amyloid precursor-like protein 2 (APLP2), influence p53 expression and activity, thereby affecting AD progression [97]. Specific miRNAs have been identified as either upregulated or downregulated in AD, influencing Aβ production by modulating BACE1 and/or APP expression. For instance, miRNAs such as miR-9, miR-29, miR-29a/b-1, miR-124, miR-101, miR-107, miR-298, and miR-328 have been associated with increased Aβ production [98–100].

MiRNAs and BACE1

In AD patients, the expression of miR-149, miR-34a-5p, miR-125b-5p, miR-15b, miR-16, miR-124, and miR-374b-5p is significantly reduced in serum and the frontal cortex, inversely correlating with BACE1 mRNA expression [101–106]. Introduction of these miRNAs into Aβ-induced AD cell models significantly decreases BACE1 mRNA levels and Aβ accumulation. Specifically, miR-149, miR-34a-5p, miR-16, miR-29c, and miR-374b-5p directly target BACE1 to exert anti-AD effects [101, 102, 105–107]. Animal model studies further corroborate these findings. In the hippocampus of SAMP8 mice, a common model for studying AD, researchers have observed the downregulation of miR-340 and the upregulation of BACE1 [108]. Additionally, in AD model mice, miR-22-3p and miR-340 have been shown to significantly inhibit BACE1 and reduce Aβ levels. MiR-22-3p indirectly affected MAPK14, while miR-340 has been verified to directly target BACE1 [108, 109].

Moreover, exogenous overexpression of miRNAs can critically influence Aβ production. For example, miR-29a expression in transgenic mice leads to reduced endogenous BACE1 levels and increased Aβ [110]. Conversely, miR-195 overexpression in N2a/APP695 cells results in decreased Aβ levels, while its inhibition increases Aβ levels. This suggests that reduced expression of specific miRNAs may enhance BACE1 expression and function, contributing to the aberrant Aβ production characteristic of AD [111]. Furthermore, overexpression of miR-186 in neural cells decreases Aβ levels by inhibiting BACE1 expression, highlighting the complex regulatory network of miRNAs in AD pathogenesis and offering potential therapeutic targets for modulating Aβ production [112].

MiRNAs and APP regulation in AD

Clinical research indicates that specific miRNAs play a crucial role in regulating amyloid APP levels, thereby influencing AD pathology. For instance, overexpression of miR-106a and miR-520c has been shown to significantly reduce APP levels in HEK-293 cells, suggesting a potential therapeutic pathway for AD by targeting APP synthesis [113]. Additionally, evidence points to the involvement of miR-16 in APP accumulation. Decreased miR-16 expression was observed to correlate with increased APP protein levels in the brains of spontaneously aged accelerated mouse P8 (SAMP8), a model of AD. Conversely, miR-16 overexpression led to reduced APP protein levels both in vitro and in vivo, highlighting its regulatory impact on APP [99]. Similarly, lower expressions of miR-17, miR-101, and miR-16 have been associated with elevated APP levels [114], underscoring the inhibitory role of these miRNAs on APP expression.

These findings illuminate the complex interplay between miRNAs and key AD pathogenic factors such as BACE1, APP, and Aβ, offering new perspectives on the disease’s etiology. However, the precise contribution of diminished miRNA levels to AD initiation remains to be fully elucidated. Beyond these miRNAs, others like miR-128 have been linked to increased Aβ levels and AD progression. Notably, miR-128 expression, alongside Aβ levels, was found to be significantly elevated in the cerebral cortex of 3xTg-AD mice compared to wild-type counterparts. In contrast, miR-128 knockout mice demonstrated improved cognitive functions relative to 3xTg-AD mice, suggesting a detrimental role of miR-128 in AD [115]. Moreover, miR-126 inhibition has shown neuroprotective effects against Aβ42 toxicity, indicating that both miR-128 and miR-126 may play critical roles in AD progression [116].

These insights into miRNA-mediated regulation of APP and Aβ production not only deepen our understanding of AD’s molecular basis but also hint at novel miRNA-targeted therapeutic strategies for managing or potentially altering the course of the disease.

MiRNAs, tau phosphorylation, and aggregation in AD

The pathological hallmark of AD is not only characterized by Aβ accumulation but also by the hyperphosphorylation of tau protein, leading to the formation of NFTs. This process is a critical event in the disease’s pathogenesis. The detrimental impact of altered miRNAs in AD extends beyond Aβ pathology to include significant associations with tau phosphorylation and pathological aggregation [117]. Tau, a protein encoded by the microtubule-associated protein tau (MAPT) gene, plays a vital role in stabilizing microtubules in neuron axons under normal conditions [118–120]. However, in AD, tau becomes hyperphosphorylated, losing its affinity for tubulin and contributing to neuronal dysfunction and degeneration [120, 121].

Landgraf et al.‘s genomic study of brain tissue miRNAs from AD patients identified significant expression changes in over 250 miRNAs across various organ systems and cell types [122]. Notably, miR-132 and miR-425-5p levels were found to be upregulated, whereas miR-124-3p and miR-512 levels were downregulated in AD brains. MiR-132, in particular, has been highlighted for its profound regulatory role within the central nervous system (CNS). Conditional deletion studies have shown that miR-132 double-knockout mice exhibit significant cognitive deficits, implicating miR-132 dysregulation in a broad spectrum of cognitive disorders [123, 124]. Furthermore, overexpression of miR-132 in neuronal models has been linked to increased neuronal apoptosis and enhanced tau phosphorylation, suggesting its pivotal role in AD pathogenesis through the modulation of tau phosphorylation pathway [125]. Similarly, miR-425-5p overexpression has been associated with increased apoptosis, activation of glycogen synthase kinase-3β (GSK-3β), and enhanced tau phosphorylation in AD models [126]. On the other hand, miR-124-3p appears to offer a neuroprotective effect by inhibiting abnormal tau hyperphosphorylation through the caveolin-1-PI3K/Akt/GSK3β pathway [127]. The reduced expression of miR-512 in late-stage AD brains, along with its association with tau protein anomalies, further underscores the complex role of miRNAs in tau pathology [128].

Additional miRNAs, such as miR-483-5p, miR-125b-5p, have been implicated in regulating signaling pathways indirectly influencing tau phosphorylation [129, 130]. For instance, miR-483-5p-mediated inhibition of ERK1/2 has been shown to reduce tau phosphorylation, linking it to tau neuropathology in AD [129]. Moreover, melatonin’s effect on tau hyperphosphorylation, potentially mediated through miR-125b-5p regulation of protein phosphatase 2A (PP2A) activity, highlights the intricate molecular interplay involved in tau regulation [130].

These findings collectively suggest that miRNAs play a critical role in AD by modulating tau phosphorylation and aggregation, offering potential therapeutic targets for intervention. The alteration in miRNA expression patterns not only affects neuronal survival but may also contribute to the accumulation of pathogenic proteins like hyperphosphorylated tau, thereby disrupting normal neuronal function and contributing to the clinical manifestations of AD.

MiRNAs and inflammatory response in AD

Inflammation significantly contributes to the pathogenesis of CNS diseases, with neuroinflammation playing a pivotal role in AD pathology [131, 132]. Glial cells, including microglia and astrocytes, are key players in the inflammatory response to Aβ toxicity [133]. Microglia, the brain’s resident macrophages, exhibit phagocytic functions that are crucial for Aβ clearance under healthy conditions. However, Aβ aggregates can induce microglial activation, leading to the release of nitric oxide (NO), reactive oxygen species (ROS), and pro-inflammatory cytokines such as IL-1β and TNF-α [134, 135]. This inflammatory response can exacerbate neuronal damage and accelerate AD pathology [136]. When activated in response to AD pathology, astrocytes transform into reactive astrocytes that produce toxic factors through the induction of their downstream target genes [137, 138]. The interaction between neurons and astrocytes, particularly through the glutamate/glutamine cycle, is essential for neurotransmission and closely linked to astrocytic energy metabolism [139, 140]. AD-induced metabolic remodeling in astrocytes significantly impacts this cycle, contributing to disease progression [141].

Recent studies have highlighted the interplay between neuroinflammation and autophagy in AD [142–144], with disruptions in autophagic lysosome maturation and transport leading to autophagic vacuole accumulation. This accumulation, indicative of incomplete autophagy, correlates with Aβ aggregate buildup and autophagic dysfunction [145]. The resulting imbalance in microglial and astrocytic activity, coupled with impaired immune interactions between neurons, affects synaptic plasticity, neuronal survival, and cognition [146].

Microglia’s role in neuroinflammation

Microglia serve dual roles in brain health: they are crucial for immune defense and maintaining homeostasis. Beyond acting as the brain’s immune sentinels, microglia contribute to neuronal proliferation, differentiation, and synaptic connection formation [147]. Under physiological conditions, microglia patrol the brain, providing immune surveillance and supporting neuronal survival. Aβ aggregates trigger microglia to undergo morphological and molecular changes, adopting a disease-associated microglial (DAM) phenotype characterized by the overexpression of specific receptors, chemokines, and cytokines [148]. Pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs), the receptor for advanced glycation end products (RAGE), and nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), play a significant role in detecting Aβ formation. For example, studies have demonstrated that TLR signaling pathways might be involved in Aβ clearance, positioning TLRs as potential therapeutic targets for AD [149, 150]. Increased RAGE expression in AD brains suggests its involvement in neuronal dysfunction and death, mediating the effects of Aβ on neurons and microglia [151]. Additionally, NLRP3 inflammasome deficiency in AD models has been shown to reduce Aβ deposition and tilt microglial responses towards an M2 phenotype, indicating the NLRP3/caspase-1 axis’s importance in AD pathogenesis [152]. The activation of PRRs leads to the activation of various transcription factors, including NF-kB, AP-1, CREB, and IRFs, which regulate a multitude of genes involved in the inflammatory response. This intricate network of microglial activation, PRR signaling, and transcription factor regulation underscores the complex role of neuroinflammation in AD and highlights the potential for targeting these pathways to modulate disease progression [153].

The role of astrocytes in neuroinflammation

Astrocytes, the most abundant glial cells in the CNS, originate from neural stem cells (NSCs) [154]. Their functions parallel those of microglia to some extent, including maintaining homeostasis and supplying neurons with metabolites and growth factors. Astrocytes play a crucial role in synaptic formation, synaptic plasticity, regulating the blood-brain barrier [155], balancing ions and fluids, and scavenging free radicals. Moreover, they are involved in bidirectional communication with neurons, essential for maintaining CNS homeostasis and neuronal survival [156]. Under pathological conditions, such as in AD, astrocytes undergo significant morphological and functional transformations, becoming reactive astrocytes. This state is characterized by cellular hypertrophy and the excessive release of neurotoxic factors. Studies have highlighted the detrimental effects of reactive astrocytes on neuronal health [157, 158]. Like microglia, astrocytes detect Aβ aggregates via TLRs and RAGE, triggering the activation of downstream genes and the production of various neurotoxic factors [159]. Aβ exposure induces astrocytes to produce ROS, nitric oxide (NO), and a range of cytokines and chemokines, exacerbating neuroinflammation and contributing to the pathology of AD [134].

MiRNAs in neuroinflammation

The inflammatory response in AD is closely linked to changes in miRNA expression. Identifying the specific miRNAs involved in the production of pro-inflammatory cytokines and proteolytic enzymes is crucial for understanding their role in AD pathology. For instance, studies have demonstrated that miR-146a overexpression in microglia can mitigate cognitive deficits, attenuate neuroinflammation, reduce Aβ levels, and prevent neuronal loss. This is achieved by promoting a shift from the M1 pro-inflammatory phenotype to the M2 anti-inflammatory phenotype [160, 161]. This shift is associated with decreased production of pro-inflammatory cytokines and enhanced phagocytosis, offering neuronal protection. Conversely, data from human AD brains indicate that increased levels of miR-146 may intensify neuroinflammation by targeting complement factor H (CFH), a key regulatory protein involved in innate immunity and inflammation, leading to a significant reduction in CFH expression [162]. Additionally, miR-132 has been implicated in the regulation of inflammation, exerting a negative regulatory effect on inflammatory factors. In models of spinal cord injury, substances like resveratrol have been shown to modulate miR-132 expression, suggesting a protective role against AD-induced inflammatory damage [163].

MiR-155, another multifunctional miRNA, has a distinct expression profile and is involved in various physiological and pathological processes, including immunity and inflammation [164, 165]. It regulates T cell function during inflammation and has been found to be highly expressed in 3xTg AD animal models. The upregulation of miR-155 leads to enhanced activation of microglia and astrocytes, triggering the release of inflammatory mediators and potentially contributing to AD progression through the modulation of T-cell functions during inflammation [166].

These insights into the roles of specific miRNAs in neuroinflammation offer potential therapeutic targets for modulating inflammatory responses in AD. Pharmacological modulation of these miRNAs could provide novel strategies for mitigating neuroinflammation and its detrimental effects on neuronal health in AD.

MiRNAs and oxidative stress in AD

Oxidative stress (OS) is a pivotal factor in the etiology of AD and other neurodegenerative disorders. It encompasses an array of detrimental events, including enhanced production of ROS, mitochondrial dysfunction, anomalies in neuronal energy metabolism, alterations in neurotrophic signaling and cellular stress responses, dysregulation of calcium handling, and impairments in autophagy [167–169]. Unlike DNA, RNA is more vulnerable to oxidative damage due to its predominantly single-stranded structure, exposing its bases to oxidative agents. Moreover, the proximity of cellular RNA to mitochondria, the primary sources of ROS, exacerbates its susceptibility to oxidative modifications. These modifications are not limited to protein-coding RNAs but also affect non-coding RNAs, including miRNAs, thus influencing the complex neurobiological landscape of the mammalian brain [170, 171].

Clinical and laboratory studies across neurodegenerative diseases like AD, Parkinson’s disease, and amyotrophic lateral sclerosis have consistently highlighted OS as a critical early pathogenic event [172, 173]. OS modulates the expression of various miRNAs, which in turn regulate genes integral to the OS response [174]. For instance, Jiao et al. discovered that a natural coumarin derivative, amphorin, upregulated miR-107 expression, leading to the inhibition of BACE1, a direct target of miR-107. This interaction resulted in reduced Aβ production, suggesting a therapeutic potential for miR-107 modulation in AD [175]. Similarly, miR-125b has been implicated in promoting APP and BACE1 expression, and consequently, Aβ accumulation and apoptosis, by influencing inflammatory and OS pathways via SPHK1 targeting [176].

Furthermore, miR-125b induces GSK3β activity and excessive tau phosphorylation by targeting NCAM, implicating it in AD progression [177]. MiRNA-146a, sensitive to NF-kB, modulates inflammation by targeting the 3′ UTR of CFH, a crucial inhibitor of brain inflammatory responses. Overexpression of miR-146a has been shown to induce tau phosphorylation and modulate superoxide dismutase 2 (SOD2) expression, underscoring its role in AD pathology [178]. Dysregulation of miR-146a, therefore, contributes to tau hyperphosphorylation, suggesting that inhibiting this miRNA could offer a new therapeutic approach for AD [179, 180]. MiR-200c emerges as a neuroprotective agent in the context of Aβ-induced endoplasmic reticulum stress, supporting cell survival and neurite outgrowth by downregulating PTEN and modulating insulin signaling pathways. This indicates that miR-200c could serve as both a biomarker and a therapeutic target in AD, highlighting the potential of miRNAs as tools for early diagnosis and treatment [181–183].

The intricate relationships between miRNAs, OS, and neurodegenerative processes in AD point to a significant role for miRNAs in cellular and biological responses to OS. Understanding these mechanisms could unveil novel therapeutic strategies centered around neuroprotective transcriptional repressors and excitatory effects associated with OS responses, offering new avenues for combating AD.

MiRNAs, mitochondrial, and synaptic dysfunction in AD

Synaptic basis of AD

The neuropathological hallmarks of AD include senile plaques composed of Aβ aggregates and NFTs formed by hyperphosphorylated tau protein within the brain [184–186]. Synaptic loss is closely associated with cognitive decline in AD [187, 188], prompting extensive research into the neurotoxic effects of Aβ and hyperphosphorylated tau on synaptic integrity and neuronal viability [189]. Synapses, crucial for neurotransmission and cognitive functions, become compromised in AD, marking synaptic dysfunction as a primary feature and a key driver of disease progression [190]. Aβ‘s impact on synaptic communication precedes synaptic loss, with Aβ oligomers disrupting neurotransmitter release—an early event leading to synaptic dysfunction [191]. Conversely, tau protein, under physiological conditions, interacts with multiple cellular components, influencing cell survival and function [192, 193]. Although NFTs comprise toxic tau forms, tau-induced neuronal dysfunction, and toxicity do not solely depend on these insoluble aggregates [194]. Emerging evidence suggests that soluble tau oligomers, rather than NFTs [195, 196], may exhibit pathological activity, interfering with essential intraneuronal transport [197].

Recent study utilizing single-nucleus RNA sequencing (snRNAseq) have identified distinct microglial profiles associated with AD pathology, linking them with Aβ and tau burdens. The activation of microglia by toxic proteins like Aβ and tau not only aims at clearing these pathogenic entities but can also overstimulate microglial defense mechanisms, exacerbating neuroinflammation and furthering neuropathological conditions [198]. Pathways such as Trem2, Cx3cr1, and the granulin precursor pathway play roles in modulating microglial responses and promoting the clearance of harmful stimuli [199]. However, when microglial clearance becomes compromised, chronic brain inflammation ensues, serving as both a biomarker and a contributor to AD progression [200].

Mitochondrial dysfunction and synaptic impairment are integral to AD’s pathophysiology, affecting neurotransmission and memory [201]. The role of miRNAs in regulating neuronal mitochondrial and synaptic functions has garnered increasing interest, with numerous miRNAs implicated in mitochondrial and synaptic dysfunctions identified in AD [190]. These miRNAs, many of which are upregulated in the disease, highlight the potential of miRNA modulation as a therapeutic strategy or biomarker for AD. The dysregulation of miRNAs may play a pivotal role in AD’s onset and progression, offering new insights into the molecular underpinnings of the disease and opening avenues for targeted interventions to mitigate mitochondrial and synaptic dysfunction in AD.

Integrating mitochondrial dynamics, biogenesis, and miRNAs in AD

Mitochondria, the cellular powerhouses, are critical for generating the bulk of cellular energy in the form of ATP, essential for numerous cellular functions [202]. Their evolutionary origin, theorized to stem from a symbiotic relationship between proto-eukaryotic cells and aerobic bacteria, highlights their integral role in eukaryotic cell biology [203]. This unique origin is supported by similarities between mitochondrial and bacterial DNA, including their mode of propagation through binary division. Over time, this symbiotic bacterium evolved into the mitochondria observed in today’s eukaryotic cells.

Mitochondrial dysfunction is a hallmark of AD, characterized by dynamic damage and impaired mitophagy, which are closely linked to synaptic damage [204]. The laboratory of Reddy and others has extensively explored how mitochondrial dysfunction contributes to AD progression, emphasizing the association between impaired mitochondrial dynamics and synaptic loss [201, 205–207]. This dysfunction includes alterations in mitochondrial DNA, protein import, and respiratory function, all contributing to the neurodegenerative process.

Recent discoveries have highlighted the presence of mitochondrial miRNAs, which regulate genes essential for mitochondrial function. These miRNAs have been implicated in the pathogenesis of AD, affecting energy production and contributing to the disease’s progression [208, 209]. For instance, miR-743a [210] and miR-23a/b [211] disrupt the tricarboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS), leading to reduced ATP production and neuronal death. Additionally, miR-210 [212], miR-338 [213], and miR-34a [214] target OXPHOS-related enzymes, further compromising neuronal energy demands. In neural cell lines, miR-16-5p has been shown to target BCL-2, an anti-apoptotic factor, inducing apoptosis and contributing to neuronal loss observed in AD [215]. The dysregulation of mitochondrial fusion protein 2 (mfn2) by miR-195 and the regulation of Nurr1 levels by miR-132 highlight the complex interplay between mitochondrial miRNAs and mitochondrial function in the context of AD [216].

Mitochondrial biogenesis is crucial for meeting the high energy demands of neurons [217], particularly in the brain, which consumes a significant portion of the body’s energy. This process is vital for sustaining continuous synaptic activity and action potential generation by neurons [218]. Kumar et al. found that miR-455-3p promotes mitochondrial biogenesis, enhancing cell survival and reducing Aβ toxicity [219]. Similarly, miR-34a [220] and miR-23a/b [221, 222] have been identified as regulators of mitochondrial biogenesis, offering neuroprotection against Aβ toxicity by modulating the SIRT1 signaling pathway.

The intricate relationship between mitochondrial dysfunction, miRNA regulation, and AD underscores the complexity of AD pathology. Mitochondrial miRNAs play a pivotal role in regulating mitochondrial dynamics, energy production, and synaptic function, directly impacting the progression of neurodegenerative diseases like AD [223]. Understanding the mechanisms by which mitochondrial dysfunction and miRNA dysregulation contribute to AD offers potential pathways for therapeutic intervention, aiming to restore mitochondrial function and neuronal health. As research continues to unravel these complex interactions, the potential for developing targeted treatments to mitigate the impact of mitochondrial dysfunction in AD grows, offering hope for future advancements in the management and treatment of this debilitating condition.

Synaptic dysfunction and mitochondrial miRNAs in AD

Synaptic activity is fundamental to brain function and neurotransmission. It underpins our ability to process information, form memories, and adapt to new experiences [224]. In AD, synaptic dysfunction is a critical pathological feature leading to cognitive decline, impaired neural processing, and ultimately, neuronal death. The intricate relationship between synaptic activity and mitochondrial function highlights the complexity of AD’s impact on neuronal health.

MiRNAs play a significant role in modulating synaptic function and neurotransmission. Specific miRNAs, such as miR-484, miR-132, and miR-212, are crucial for maintaining synaptic integrity and facilitating neurotransmitter release. miR-132 and miR-212, in particular, have been shown to enhance neurotransmitter levels, thereby supporting efficient neural signaling. However, in AD, the dysregulation of these miRNAs contributes to a decline in neurotransmitter availability, limiting neural processing capabilities and exacerbating cognitive deficits [225]. Moreover, Wingo et al. found that lower miR-484 levels were associated not only with a higher probability of having AD but also with greater depressive symptoms [226].

The role of miRNAs extends beyond the regulation of synaptic activity to encompass mitochondrial functions critical for energy production and cellular health. Mitochondrial miRNAs are of particular interest due to their potential involvement in AD pathogenesis. These miRNAs regulate genes encoding proteins essential for mitochondrial dynamics, energy metabolism, and apoptosis, directly impacting neuronal survival and function. While the significance of mitochondrial miRNAs in regulating mitochondrial health is well recognized, their specific contributions to synaptic functions remain less understood. Current knowledge on how mitochondrial miRNAs influence processes like mitochondrial transport, calcium signaling, and synaptic vesicle formation is limited. These processes are vital for effective neurotransmission and synaptic plasticity, suggesting that mitochondrial miRNAs could play a role in modulating these critical aspects of neuronal function.

The investigation into miRNAs associated with synaptic activity, neurotransmission, synaptic plasticity, and neurotoxicity has revealed only a handful of candidates. This gap in knowledge presents a significant opportunity for research aimed at identifying new miRNAs involved in these processes and understanding their regulation in the context of AD. Unraveling the specific roles of mitochondrial miRNAs in synaptic dysfunction could shed light on the molecular mechanisms driving cognitive decline in AD and offer new targets for therapeutic intervention.

Interestingly, it has been suggested that a complex interaction exists between miRNAs, mitochondrial dysfunction, and oxidative stress. On the one hand, miRNAs can regulate mitochondrial function, thus affecting the degree of oxidative stress; on the other hand, mitochondrial dysfunction and oxidative stress also affect miRNA expression and function [227, 228]. This interactive relationship plays an important role in balancing the redox state and maintaining cellular homeostasis within the cell, which is of great significance for cell survival and function [229]. The bidirectional influence between miRNAs and mitochondrial health highlights the importance of these molecules in the cellular response to oxidative stress and their potential as therapeutic targets for diseases involving mitochondrial dysfunction.

miRNAs and APOE4 in AD

The APOE4 allele is recognized as the most significant genetic risk factor for sporadic Alzheimer’s disease (sAD) [230], with its role first proposed by Strittmatter and Roses and subsequently supported by various genome-wide association studies (GWAS), cellular, and animal model research [231–234]. APOE’s primary function in the brain involves the transportation of cholesterol within high-density lipoprotein particles, but its polymorphic forms, namely APOE2, APOE3, and APOE4, show varied associations with AD risk, with APOE4 being strongly linked to increased susceptibility to the disease [235].

APOE4’s contribution to AD pathogenesis is multifaceted, affecting lipid and lipoprotein metabolism and influencing the plasma levels of APOE. Notably, the presence of APOE4 alleles is inversely related to miR-107 levels in AD patients, suggesting a genetic interaction that modulates disease risk and progression. The APOE E3/E3 genotype, conversely, is associated with higher APOE concentrations and miR-107 levels, indicating a protective or neutral effect regarding AD. Recent studies have illuminated the role of specific miRNAs in modulating the effects of APOE4 in AD [236–238]. For instance, the expression level of miR-195 in brain tissue and cerebrospinal fluid samples from AD patients carrying the APOE4 allele is significantly lower compared to those without the allele. This reduction in miR-195 levels correlates negatively with cognitive performance, as measured by the Mini-Mental State Examination (MMSE) score. However, upregulation of miR-195 in animal models expressing the APOE4 allele has shown promising results, including ameliorated cognitive deficits, reduced amyloid plaque burden, and decreased tau hyperphosphorylation [237]. Furthermore, the expression levels of miR-203, phosphorylated tau (p-Tau), and APOE4 significantly increase in the brain tissue of mice subjected to traumatic brain injury (TBI), linking TBI with an elevated risk of AD pathology in the context of APOE4. The use of miR-203 inhibitors has been shown to reduce the expression of APOE4 and p-Tau levels, improving hippocampal long-term potentiation (LTP) defects and ameliorating learning and memory dysfunctions induced by TBI [238].

The intricate interplay between APOE4, miRNAs, and AD pathology underscores the complexity of genetic and molecular mechanisms contributing to the disease. APOE4 not only influences lipid metabolism and amyloid-beta deposition but also interacts with specific miRNAs to modulate disease progression and severity. These findings highlight the potential of targeting miRNAs as a therapeutic strategy to mitigate the adverse effects of APOE4 in AD, offering new avenues for research and treatment development. Understanding the regulatory roles of miRNAs in the context of APOE4 can provide insights into personalized medicine approaches for managing AD, tailoring interventions based on genetic risk factors and molecular pathologies.

Conclusion and future perspective on AD research and miRNAs

AD, traditionally characterized by the concurrent presence of Aβ plaques and tau protein tangles, is undergoing a paradigm shift in its conceptual understanding. The simplistic linear causality proposed by the original amyloid hypothesis is being reconsidered, giving way to a more nuanced view that incorporates age-related, protective, and disease-promoting factors interacting with the disease’s core mechanisms. This paper has discussed critical elements in AD pathogenesis, including Aβ deposition, intracellular hyperphosphorylated tau aggregation, synaptic loss, neuroinflammation, OS, and genetic variations, all of which are intertwined with the dysregulation of a myriad of miRNAs (Fig. 2). MiRNAs have emerged as pivotal molecules in the regulatory networks underlying AD’s complex pathology. Their ability to modulate key pathogenic processes presents a promising avenue for research and therapeutic intervention. Unlike the more complex molecular neuroimaging techniques, such as structural magnetic resonance imaging (MRI) and positron emission tomography (PET), analyzing miRNAs in bodily fluids offers a relatively straightforward and minimally invasive method for studying AD [239, 240]. This simplicity, combined with their regulatory significance, positions miRNAs as valuable biomarkers for early detection and progression monitoring of AD.Fig. 2 Summary of miRNAs and the targets in AD.

Specific microRNAs play key roles in the development of Alzheimer's disease (AD), regulating Aβ deposition, Tau hyperphosphorylation, synaptic dysfunction, neuroinflammation, oxidative stress, and genetic factors. All these factors are intertwined with the dysregulation of myriad miRNAs. These microRNAs, as biomarkers, not only help in early diagnosis and disease monitoring, but may also become new therapeutic targets and provide new ideas for intervention strategies in Alzheimer’s disease. [miR microRNA, APP amyloid precursor protein, BACE1 beta-secretase 1, PS1/2 Presenilin1/2, TNF-α tumor necrosis factor α, IL interleukin, TGF-β transforming growth factor β, NF-κB nuclear factor Kappa B, SOCS suppressor of cytokine signaling, STAT signal transducer and activator of transcription, OH hydroxyl radical, O2 oxygen, NO nitric oxide, PHF paired helical filaments, NFT neurofibrillary tangle, SOD2 superoxide dismutase 2, GSK3β glycogen synthase kinase 3β, NCAM neural cell adhesion molecule, BCL-2 B-cell lymphoma-2, MFN2 mitochondrial fusion protein 2, MDH2 malate dehydrogenase, MCL1 myeloid cell leukemia 1, ERK1/2 extracellular regulated protein kinases1/2].

To evaluate the potential of miRNAs as early non-invasive markers for AD diagnosis, a meta-analysis was conducted to screen differentially expressed miRNAs in blood exosomes of AD patients. The study revealed significantly lower levels of blood miR-212 and miR-132 in AD patients compared to healthy controls [241]. Conversely, serum levels of exosomal miR-135a, miR-193b, and miR-384 were markedly increased in AD patients [242]. Several miRNAs showing significant differential expression were selected for validation and diagnostic testing. Notably, miR-132 demonstrated a robust ability to distinguish AD from controls in blood assays [243]. Most AD patients exhibit memory cognitive decline, often linked to impaired neurogenesis. Walgrave et al. identified miR-132 as one of the most consistently downregulated miRNAs in AD. Decreased miR-132 expression was shown to impair adult hippocampal neurogenesis (AHN), a process crucial for memory and cognitive plasticity. In mouse models, miR-132 replacement in the AD hippocampus restored AHN and ameliorated associated memory deficits. This effect was influenced by Aβ pathology [244]. Deng et al. found that miR-132 expression was significantly downregulated, while MAPK1 expression was upregulated in an AD rat model. They suggested miR-132 and MAPK1 have specific binding sites, and that miR-132 can inhibit MAPK1 expression. This inhibition reduced hippocampal oxidative stress and iNOS expression, thereby improving cognitive function in AD rats [245]. El Fatimy et al. demonstrated that miR-132 exerts neuroprotective effects against AD through multiple signaling pathways. miR-132 mitigates tau protein pathology associated with tauopathy, reduces phosphorylated tau in P301S tau transgenic mice, and enhances long-term potentiation [246]. These results suggests that modulation of miR-132 expression could provide new therapeutic strategies for AD.

A comprehensive understanding of specific miRNAs’ regulatory roles in AD is essential for advancing therapeutic strategies. Future research should aim to elucidate the intricate molecular mechanisms by which miRNAs influence AD pathogenesis, with a focus on their interaction with known risk factors and pathological markers. The integration of large-scale GWAS and transcriptomics studies has significantly advanced our understanding of the genetic basis of AD [247]. By identifying associations between single nucleotide polymorphisms and AD risk, as well as differentially expressed genes associated with AD, researchers have gained insights into the molecular mechanisms underlying the disease. One promising approach involves analyzing molecular interactions within the context of disease networks, known as interactomes [248]. This method considers the collective dysfunction of disease-related genes and their interactions, providing a comprehensive view of AD pathophysiology at multiple levels [249].

Studies have revealed associations between AD and various molecular networks, including those involved in lipid metabolism and immune dysfunction. For instance, the APOE ε4 allele has been implicated in lipid metabolism, while immune dysfunction in microglia has also been linked to AD [250–253]. Recent research has identified a significant association between genetic variants in TMEM106B and APOE mRNA levels in the human brain cortex, highlighting its potential role in AD [254]. TMEM106B has also been implicated as a risk gene for frontotemporal lobar degeneration (FTLD) [255]. Further investigation has revealed specific microRNA regulators of TMEM106B, such as miR-132 and miR-212, which are attenuated in FTLD. Overexpression of TMEM106B disrupts the endosomal-lysosomal pathway and alters intracellular protein levels, suggesting its involvement in AD pathogenesis [256].

By combining genomics, proteomics, and bioinformatics methods, we can construct miRNA-target gene networks, revealing the regulatory network of miRNAs in the pathogenesis of AD. This approach will allow us to study the regulatory pathways and signaling of miRNAs, providing a comprehensive understanding of the complex mechanisms involved in AD. Ultimately, this knowledge will support the development of relevant therapeutic strategies for AD, offering significant insights into the disease’s pathogenesis and potential treatment avenues.

The potential of miRNAs as therapeutic agents in AD is vast but yet to be fully realized. Developing miRNA-based therapies will involve overcoming challenges related to delivery, targeting specificity, and off-target effects. Innovative approaches, such as nanoparticle-based delivery systems, could provide solutions to these challenges, enabling precise modulation of pathological miRNA levels within the brain. As the field moves forward, bridging the gap between research findings and clinical applications will be crucial. This transition will necessitate rigorous clinical trials to validate the efficacy and safety of miRNA-based diagnostics and therapeutics. Furthermore, personalized medicine approaches, which tailor interventions based on individual genetic and molecular profiles, could significantly enhance treatment outcomes for AD patients.

In conclusion, miRNAs represent a frontier in AD research with the potential to revolutionize diagnostics and therapeutics. As our understanding of their roles in AD deepens, the prospects for developing effective interventions to delay, halt, or reverse the progression of this devastating disease become increasingly tangible. The journey from bench to bedside is complex and fraught with challenges, but the potential rewards for patients and society are immense, driving the continued pursuit of knowledge in this promising area of neuroscience.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (82071676), the NSFC-RGC Joint Research Scheme (32061160472).

Author contributions

YC conceived and designed this study; YBL and QF analyzed and collated the data; MG and YD participated in the literature call and collected samples. The YBL drafted the manuscript with critical revisions from YWC and YC.

Data availability

Data available on request from the authors.

Competing interests

The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Prince M Bryce R Albanese E Wimo A Ribeiro W Ferri CP The global prevalence of dementia: a systematic review and metaanalysis Alzheimers Dement 2013 9 63 75.e2 10.1016/j.jalz.2012.11.007 23305823
Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9:63–75.e2.23305823 10.1016/j.jalz.2012.11.007
2. Sugino H Watanabe A Amada N Yamamoto M Ohgi Y Kostic D Global trends in Alzheimer disease clinical development: increasing the probability of success Clin Ther 2015 37 1632 42 10.1016/j.clinthera.2015.07.006 26243073
Sugino H, Watanabe A, Amada N, Yamamoto M, Ohgi Y, Kostic D, et al. Global trends in Alzheimer disease clinical development: increasing the probability of success. Clin Ther. 2015;37:1632–42.26243073 10.1016/j.clinthera.2015.07.006
3. Long JM Holtzman DM Alzheimer disease: an update on pathobiology and treatment strategies Cell 2019 179 312 39 10.1016/j.cell.2019.09.001 31564456
Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179:312–39.31564456 10.1016/j.cell.2019.09.001
4. Puzzo D Piacentini R Fá M Gulisano W Li Puma DD Staniszewski A LTP and memory impairment caused by extracellular Aβ and Tau oligomers is APP-dependent eLife 2017 6 e26991 10.7554/eLife.26991 28696204
Puzzo D, Piacentini R, Fá M, Gulisano W, Li Puma DD, Staniszewski A, et al. LTP and memory impairment caused by extracellular Aβ and Tau oligomers is APP-dependent. eLife. 2017;6:e26991.28696204 10.7554/eLife.26991
5. Arvanitakis Z Shah RC Bennett DA Diagnosis and management of dementia: review JAMA 2019 322 1589 99 10.1001/jama.2019.4782 31638686
Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and management of dementia: review. JAMA. 2019;322:1589–99.31638686 10.1001/jama.2019.4782
6. Nordberg A PET imaging of amyloid in Alzheimer’s disease Lancet Neurol 2004 3 519 27 10.1016/S1474-4422(04)00853-1 15324720
Nordberg A. PET imaging of amyloid in Alzheimer’s disease. Lancet Neurol. 2004;3:519–27.15324720 10.1016/S1474-4422(04)00853-1
7. Nagaraj S Zoltowska KM Laskowska-Kaszub K Wojda U microRNA diagnostic panel for Alzheimer’s disease and epigenetic trade-off between neurodegeneration and cancer Ageing Res Rev 2019 49 125 43 10.1016/j.arr.2018.10.008 30391753
Nagaraj S, Zoltowska KM, Laskowska-Kaszub K, Wojda U. microRNA diagnostic panel for Alzheimer’s disease and epigenetic trade-off between neurodegeneration and cancer. Ageing Res Rev. 2019;49:125–43.30391753 10.1016/j.arr.2018.10.008
8. Piscopo P Lacorte E Feligioni M Mayer F Crestini A Piccolo L MicroRNAs and mild cognitive impairment: a systematic review Ageing Res Rev 2019 50 131 41 10.1016/j.arr.2018.11.005 30472218
Piscopo P, Lacorte E, Feligioni M, Mayer F, Crestini A, Piccolo L, et al. MicroRNAs and mild cognitive impairment: a systematic review. Ageing Res Rev. 2019;50:131–41.30472218 10.1016/j.arr.2018.11.005
9. Lehmann SM Krüger C Park B Derkow K Rosenberger K Baumgart J An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration Nat Neurosci 2012 15 827 35 10.1038/nn.3113 22610069
Lehmann SM, Krüger C, Park B, Derkow K, Rosenberger K, Baumgart J, et al. An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nat Neurosci. 2012;15:827–35.22610069 10.1038/nn.3113
10. Liu X Jiao B Shen L The epigenetics of Alzheimer’s disease: factors and therapeutic implications Front Genet 2018 9 579 10.3389/fgene.2018.00579 30555513
Liu X, Jiao B, Shen L. The epigenetics of Alzheimer’s disease: factors and therapeutic implications. Front Genet. 2018;9:579.30555513 10.3389/fgene.2018.00579
11. Wang M Qin L Tang B MicroRNAs in Alzheimer’s disease Front Genet 2019 10 153 10.3389/fgene.2019.00153 30881384
Wang M, Qin L, Tang B. MicroRNAs in Alzheimer’s disease. Front Genet. 2019;10:153.30881384 10.3389/fgene.2019.00153
12. Jung YY Kim KC Park MH Seo Y Park H Park MH Atherosclerosis is exacerbated by chitinase-3-like-1 in amyloid precursor protein transgenic mice Theranostics 2018 8 749 66 10.7150/thno.20183 29344304
Jung YY, Kim KC, Park MH, Seo Y, Park H, Park MH, et al. Atherosclerosis is exacerbated by chitinase-3-like-1 in amyloid precursor protein transgenic mice. Theranostics. 2018;8:749–66.29344304 10.7150/thno.20183
13. Mendes-Silva AP Pereira KS Tolentino-Araujo GT Nicolau Ede S Silva-Ferreira CM Teixeira AL Shared biologic pathways between Alzheimer disease and major depression: a systematic review of MicroRNA expression studies Am J Geriatr Psychiatry 2016 24 903 12 10.1016/j.jagp.2016.07.017 27591915
Mendes-Silva AP, Pereira KS, Tolentino-Araujo GT, Nicolau Ede S, Silva-Ferreira CM, Teixeira AL, et al. Shared biologic pathways between Alzheimer disease and major depression: a systematic review of MicroRNA expression studies. Am J Geriatr Psychiatry. 2016;24:903–12.27591915 10.1016/j.jagp.2016.07.017
14. Gholami A Dehghan G Rashtbari S Jouyban A Probing the interactions of lamotrigine and phenobarbital with tau protein: experimental and molecular modeling studies Iran J Pharm Res 2022 21 e129599 10.5812/ijpr-129599 36945338
Gholami A, Dehghan G, Rashtbari S, Jouyban A. Probing the interactions of lamotrigine and phenobarbital with tau protein: experimental and molecular modeling studies. Iran J Pharm Res. 2022;21:e129599.36945338 10.5812/ijpr-129599
15. Ashrafian H Zadeh EH Khan RH Review on Alzheimer’s disease: Inhibition of amyloid beta and tau tangle formation Int J Biol Macromol 2021 167 382 94 10.1016/j.ijbiomac.2020.11.192 33278431
Ashrafian H, Zadeh EH, Khan RH. Review on Alzheimer’s disease: Inhibition of amyloid beta and tau tangle formation. Int J Biol Macromol. 2021;167:382–94.33278431 10.1016/j.ijbiomac.2020.11.192
16. Funamoto S Tagami S Okochi M Morishima-Kawashima M Successive cleavage of β-amyloid precursor protein by γ-secretase Semin Cell Dev Biol 2020 105 64 74 10.1016/j.semcdb.2020.04.002 32354467
Funamoto S, Tagami S, Okochi M, Morishima-Kawashima M. Successive cleavage of β-amyloid precursor protein by γ-secretase. Semin Cell Dev Biol. 2020;105:64–74.32354467 10.1016/j.semcdb.2020.04.002
17. Nguyen KV β-Amyloid precursor protein (APP) and the human diseases AIMS Neurosci 2019 6 273 81 10.3934/Neuroscience.2019.4.273 32341983
Nguyen KV. β-Amyloid precursor protein (APP) and the human diseases. AIMS Neurosci. 2019;6:273–81.32341983 10.3934/Neuroscience.2019.4.273
18. Ristori E Donnini S Ziche M New insights into blood-brain barrier maintenance: the homeostatic role of β-amyloid precursor protein in cerebral vasculature Front Physiol 2020 11 1056 10.3389/fphys.2020.01056 32973564
Ristori E, Donnini S, Ziche M. New insights into blood-brain barrier maintenance: the homeostatic role of β-amyloid precursor protein in cerebral vasculature. Front Physiol. 2020;11:1056.32973564 10.3389/fphys.2020.01056
19. Parihar MS Hemnani T Alzheimer’s disease pathogenesis and therapeutic interventions J Clin Neurosci 2004 11 456 67 10.1016/j.jocn.2003.12.007 15177383
Parihar MS, Hemnani T. Alzheimer’s disease pathogenesis and therapeutic interventions. J Clin Neurosci. 2004;11:456–67.15177383 10.1016/j.jocn.2003.12.007
20. Mockett BG Ryan MM The therapeutic potential of the neuroactive peptides of soluble amyloid precursor protein-alpha in Alzheimer’s disease and related neurological disorders Semin Cell Dev Biol 2023 139 93 101 10.1016/j.semcdb.2022.05.014 35654665
Mockett BG, Ryan MM. The therapeutic potential of the neuroactive peptides of soluble amyloid precursor protein-alpha in Alzheimer’s disease and related neurological disorders. Semin Cell Dev Biol. 2023;139:93–101.35654665 10.1016/j.semcdb.2022.05.014
21. Tamagno E Guglielmotto M Vasciaveo V Tabaton M Oxidative stress and beta amyloid in Alzheimer’s disease. Which comes first: the chicken or the egg? Antioxidants 2021 10 1479 10.3390/antiox10091479 34573112
Tamagno E, Guglielmotto M, Vasciaveo V, Tabaton M. Oxidative stress and beta amyloid in Alzheimer’s disease. Which comes first: the chicken or the egg? Antioxidants. 2021;10:1479.34573112 10.3390/antiox10091479
22. Tsai AP Dong C Lin PB Messenger EJ Casali BT Moutinho M PLCG2 is associated with the inflammatory response and is induced by amyloid plaques in Alzheimer’s disease Genome Med 2022 14 17 10.1186/s13073-022-01022-0 35180881
Tsai AP, Dong C, Lin PB, Messenger EJ, Casali BT, Moutinho M, et al. PLCG2 is associated with the inflammatory response and is induced by amyloid plaques in Alzheimer’s disease. Genome Med. 2022;14:17.35180881 10.1186/s13073-022-01022-0
23. Bhatia V Sharma S Role of mitochondrial dysfunction, oxidative stress and autophagy in progression of Alzheimer’s disease J Neurol Sci 2021 421 117253 10.1016/j.jns.2020.117253 33476985
Bhatia V, Sharma S. Role of mitochondrial dysfunction, oxidative stress and autophagy in progression of Alzheimer’s disease. J Neurol Sci. 2021;421:117253.33476985 10.1016/j.jns.2020.117253
24. Kim SH Lim KH Yang S Joo JY Boosting of tau protein aggregation by CD40 and CD48 gene expression in Alzheimer’s disease FASEB J 2023 37 e22702 10.1096/fj.202201197R 36520044
Kim SH, Lim KH, Yang S, Joo JY. Boosting of tau protein aggregation by CD40 and CD48 gene expression in Alzheimer’s disease. FASEB J. 2023;37:e22702.36520044 10.1096/fj.202201197R
25. Ariafar S Makhdoomi S Mohammadi M Arsenic and tau phosphorylation: a mechanistic review Biol Trace Elem Res 2023 201 5708 20 10.1007/s12011-023-03634-y 37211576
Ariafar S, Makhdoomi S, Mohammadi M. Arsenic and tau phosphorylation: a mechanistic review. Biol Trace Elem Res. 2023;201:5708–20.37211576 10.1007/s12011-023-03634-y
26. Moore KBE Hung TJ Fortin JS Hyperphosphorylated tau (p-tau) and drug discovery in the context of Alzheimer’s disease and related tauopathies Drug Discov Today 2023 28 103487 10.1016/j.drudis.2023.103487 36634842
Moore KBE, Hung TJ, Fortin JS. Hyperphosphorylated tau (p-tau) and drug discovery in the context of Alzheimer’s disease and related tauopathies. Drug Discov Today. 2023;28:103487.36634842 10.1016/j.drudis.2023.103487
27. Zhang W Shen XY Zhang WW Chen H Xu WP Wei W Corrigendum to “Di-(2-ethylhexyl) phthalate could disrupt the insulin signaling pathway in liver of SD rats and L02 cells via PPARγ“ Toxicol Appl Pharmacol 2022 449 116091 10.1016/j.taap.2022.116091 35659896
Zhang W, Shen XY, Zhang WW, Chen H, Xu WP, Wei W. Corrigendum to “Di-(2-ethylhexyl) phthalate could disrupt the insulin signaling pathway in liver of SD rats and L02 cells via PPARγ“. Toxicol Appl Pharmacol. 2022;449:116091. 10.1016/j. taap.2016.12.01035659896 10.1016/j.taap.2022.116091
28. Lee S Cho HJ Ryu JH Innate immunity and cell death in Alzheimer’s disease ASN Neuro 2021 13 17590914211051908 10.1177/17590914211051908 34668411
Lee S, Cho HJ, Ryu JH. Innate immunity and cell death in Alzheimer’s disease. ASN Neuro. 2021;13:17590914211051908.34668411 10.1177/17590914211051908
29. Tellechea P Pujol N Esteve-Belloch P Echeveste B García-Eulate MR Arbizu J Early- and late-onset Alzheimer disease: Are they the same entity? Neurologia 2018 33 244 53 10.1016/j.nrl.2015.08.002 26546285
Tellechea P, Pujol N, Esteve-Belloch P, Echeveste B, García-Eulate MR, Arbizu J, et al. Early- and late-onset Alzheimer disease: Are they the same entity? Neurologia. 2018;33:244–53.26546285 10.1016/j.nrl.2015.08.002
30. Dong HK Gim JA Yeo SH Kim HS Integrated late onset Alzheimer’s disease (LOAD) susceptibility genes: cholesterol metabolism and trafficking perspectives Gene 2017 597 10 16 10.1016/j.gene.2016.10.022 27773727
Dong HK, Gim JA, Yeo SH, Kim HS. Integrated late onset Alzheimer’s disease (LOAD) susceptibility genes: cholesterol metabolism and trafficking perspectives. Gene. 2017;597:10–16.27773727 10.1016/j.gene.2016.10.022
31. Mendez MF Early-onset Alzheimer’s disease: nonamnestic subtypes and type 2 AD Arch Med Res 2012 43 677 85 10.1016/j.arcmed.2012.11.009 23178565
Mendez MF. Early-onset Alzheimer’s disease: nonamnestic subtypes and type 2 AD. Arch Med Res. 2012;43:677–85.23178565 10.1016/j.arcmed.2012.11.009
32. Mendez MF Lee AS Karve SJ Shapira JS Nonamnestic presentations of early-onset Alzheimer’s disease Am J Alzheimers Dis Other Demen 2012 27 413 20 10.1177/1533317512454711 22871906
Mendez MF, Lee AS, Karve SJ, Shapira JS. Nonamnestic presentations of early-onset Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2012;27:413–20.22871906 10.1177/1533317512454711
33. Joubert S Gour N Guedj E Didic M Guériot C Koric L Early-onset and late-onset Alzheimer’s disease are associated with distinct patterns of memory impairment Cortex 2016 74 217 32 10.1016/j.cortex.2015.10.014 26694580
Joubert S, Gour N, Guedj E, Didic M, Guériot C, Koric L, et al. Early-onset and late-onset Alzheimer’s disease are associated with distinct patterns of memory impairment. Cortex. 2016;74:217–32.26694580 10.1016/j.cortex.2015.10.014
34. Jiang H Jayadev S Lardelli M Newman M A review of the familial Alzheimer’s disease locus PRESENILIN 2 and its relationship to PRESENILIN 1 J Alzheimers Dis 2018 66 1323 39 10.3233/JAD-180656 30412492
Jiang H, Jayadev S, Lardelli M, Newman M. A review of the familial Alzheimer’s disease locus PRESENILIN 2 and its relationship to PRESENILIN 1. J Alzheimers Dis. 2018;66:1323–39.30412492 10.3233/JAD-180656
35. Williams T Borchelt DR Chakrabarty P Therapeutic approaches targeting Apolipoprotein E function in Alzheimer’s disease Mol Neurodegener 2020 15 8 10.1186/s13024-020-0358-9 32005122
Williams T, Borchelt DR, Chakrabarty P. Therapeutic approaches targeting Apolipoprotein E function in Alzheimer’s disease. Mol Neurodegener. 2020;15:8.32005122 10.1186/s13024-020-0358-9
36. Cash MK Rockwood K Fisk JD Darvesh S Clinicopathological correlations and cholinesterase expression in early-onset familial Alzheimer’s disease with the presenilin 1 mutation, Leu235Pro Neurobiol Aging 2021 103 31 41 10.1016/j.neurobiolaging.2021.02.025 33789210
Cash MK, Rockwood K, Fisk JD, Darvesh S. Clinicopathological correlations and cholinesterase expression in early-onset familial Alzheimer’s disease with the presenilin 1 mutation, Leu235Pro. Neurobiol Aging. 2021;103:31–41.33789210 10.1016/j.neurobiolaging.2021.02.025
37. Yang W Wu PF Ma JX Liao MJ Xu LS Xu MH Presenilin1 exerts antiproliferative effects by repressing the Wnt/β-catenin pathway in glioblastoma Cell Commun Signal 2020 18 22 10.1186/s12964-019-0501-9 32046730
Yang W, Wu PF, Ma JX, Liao MJ, Xu LS, Xu MH, et al. Presenilin1 exerts antiproliferative effects by repressing the Wnt/β-catenin pathway in glioblastoma. Cell Commun Signal. 2020;18:22.32046730 10.1186/s12964-019-0501-9
38. Lanfranco MF Ng CA Rebeck GW ApoE lipidation as a therapeutic target in Alzheimer’s disease Int J Mol Sci 2020 21 6336 10.3390/ijms21176336 32882843
Lanfranco MF, Ng CA, Rebeck GW. ApoE lipidation as a therapeutic target in Alzheimer’s disease. Int J Mol Sci. 2020;21:6336.32882843 10.3390/ijms21176336
39. Saunders TS Jenkins N Blennow K Ritchie C Muniz-Terrera G Interactions between apolipoprotein E, sex, and amyloid-beta on cerebrospinal fluid p-tau levels in the European prevention of Alzheimer’s dementia longitudinal cohort study (EPAD LCS) EeBioMedicine 2022 83 104241 10.1016/j.ebiom.2022.104241
Saunders TS, Jenkins N, Blennow K, Ritchie C, Muniz-Terrera G. Interactions between apolipoprotein E, sex, and amyloid-beta on cerebrospinal fluid p-tau levels in the European prevention of Alzheimer’s dementia longitudinal cohort study (EPAD LCS). EeBioMedicine. 2022;83:104241.10.1016/j.ebiom.2022.104241
40. Troutwine BR Hamid L Lysaker CR Strope TA Wilkins HM Apolipoprotein E and Alzheimer’s disease Acta Pharm Sin B 2022 12 496 510 10.1016/j.apsb.2021.10.002 35256931
Troutwine BR, Hamid L, Lysaker CR, Strope TA, Wilkins HM. Apolipoprotein E and Alzheimer’s disease. Acta Pharm Sin B. 2022;12:496–510.35256931 10.1016/j.apsb.2021.10.002
41. Nakamura T Kawarabayashi T Ueda T Shimomura S Hoshino M Itoh K Plasma ApoE4 levels are lower than ApoE2 and ApoE3 levels, and not associated with plasma Aβ40/42 ratio as a biomarker of amyloid-β amyloidosis in Alzheimer’s disease J Alzheimers Dis 2023 93 333 48 10.3233/JAD-220996 36970894
Nakamura T, Kawarabayashi T, Ueda T, Shimomura S, Hoshino M, Itoh K, et al. Plasma ApoE4 levels are lower than ApoE2 and ApoE3 levels, and not associated with plasma Aβ40/42 ratio as a biomarker of amyloid-β amyloidosis in Alzheimer’s disease. J Alzheimers Dis. 2023;93:333–48.36970894 10.3233/JAD-220996
42. Bonaterra-Pastra A Benítez S Pancorbo O Rodríguez-Luna D Vert C Rovira A Association of candidate genetic variants and circulating levels of ApoE/ApoJ with common neuroimaging features of cerebral amyloid angiopathy Front Aging Neurosci 2023 15 1134399 10.3389/fnagi.2023.1134399 37113571
Bonaterra-Pastra A, Benítez S, Pancorbo O, Rodríguez-Luna D, Vert C, Rovira A, et al. Association of candidate genetic variants and circulating levels of ApoE/ApoJ with common neuroimaging features of cerebral amyloid angiopathy. Front Aging Neurosci. 2023;15:1134399.37113571 10.3389/fnagi.2023.1134399
43. Alagarsamy J Jaeschke A Hui DY Apolipoprotein E in cardiometabolic and neurological health and diseases Int J Mol Sci 2022 23 9892 10.3390/ijms23179892 36077289
Alagarsamy J, Jaeschke A, Hui DY. Apolipoprotein E in cardiometabolic and neurological health and diseases. Int J Mol Sci. 2022;23:9892.36077289 10.3390/ijms23179892
44. Wu L Zhang Y Zhao H Rong G Huang P Wang F Dissecting the association of apolipoprotein E gene polymorphisms with type 2 diabetes mellitus and coronary artery disease Front Endocrinol 2022 13 838547 10.3389/fendo.2022.838547
Wu L, Zhang Y, Zhao H, Rong G, Huang P, Wang F, et al. Dissecting the association of apolipoprotein E gene polymorphisms with type 2 diabetes mellitus and coronary artery disease. Front Endocrinol. 2022;13:838547.10.3389/fendo.2022.838547
45. Graves AB White E Koepsell TD Reifler BV van Belle G Larson EB The association between head trauma and Alzheimer’s disease Am J Epidemiol 1990 131 491 501 10.1093/oxfordjournals.aje.a115523 2405648
Graves AB, White E, Koepsell TD, Reifler BV, van Belle G, Larson EB, et al. The association between head trauma and Alzheimer’s disease. Am J Epidemiol. 1990;131:491–501.2405648 10.1093/oxfordjournals.aje.a115523
46. Shokhirev MN Johnson AA An integrative machine-learning meta-analysis of high-throughput omics data identifies age-specific hallmarks of Alzheimer’s disease Ageing Res Rev 2022 81 101721 10.1016/j.arr.2022.101721 36029998
Shokhirev MN, Johnson AA. An integrative machine-learning meta-analysis of high-throughput omics data identifies age-specific hallmarks of Alzheimer’s disease. Ageing Res Rev. 2022;81:101721.36029998 10.1016/j.arr.2022.101721
47. Liu RM Aging, cellular senescence, and Alzheimer’s disease Int J Mol Sci 2022 23 1989 10.3390/ijms23041989 35216123
Liu RM. Aging, cellular senescence, and Alzheimer’s disease. Int J Mol Sci. 2022;23:1989.35216123 10.3390/ijms23041989
48. Zhang XX Tian Y Wang ZT Ma YH Tan L Yu JT The epidemiology of Alzheimer’s disease modifiable risk factors and prevention J Prev Alzheimers Dis 2021 8 313 21 34101789
Zhang XX, Tian Y, Wang ZT, Ma YH, Tan L, Yu JT. The epidemiology of Alzheimer’s disease modifiable risk factors and prevention. J Prev Alzheimers Dis. 2021;8:313–21.34101789
49. Askarova S Umbayev B Masoud AR Kaiyrlykyzy A Safarova Y Tsoy A The links between the gut microbiome, aging, modern lifestyle and Alzheimer’s disease Front Cell Infect Microbiol 2020 10 104 10.3389/fcimb.2020.00104 32257964
Askarova S, Umbayev B, Masoud AR, Kaiyrlykyzy A, Safarova Y, Tsoy A, et al. The links between the gut microbiome, aging, modern lifestyle and Alzheimer’s disease. Front Cell Infect Microbiol. 2020;10:104.32257964 10.3389/fcimb.2020.00104
50. Bhatti GK Reddy AP Reddy PH Bhatti JS Lifestyle modifications and nutritional interventions in aging-associated cognitive decline and Alzheimer’s disease Front Aging Neurosci 2019 11 369 10.3389/fnagi.2019.00369 31998117
Bhatti GK, Reddy AP, Reddy PH, Bhatti JS. Lifestyle modifications and nutritional interventions in aging-associated cognitive decline and Alzheimer’s disease. Front Aging Neurosci. 2019;11:369.31998117 10.3389/fnagi.2019.00369
51. Xie C Feng Y Alcohol consumption and risk of Alzheimer’s disease: a dose-response meta-analysis Geriatr Gerontol Int 2022 22 278 85 10.1111/ggi.14357 35171516
Xie C, Feng Y. Alcohol consumption and risk of Alzheimer’s disease: a dose-response meta-analysis. Geriatr Gerontol Int. 2022;22:278–85.35171516 10.1111/ggi.14357
52. Pal I Dey SG The role of heme and copper in Alzheimer’s disease and type 2 diabetes mellitus JACS Au 2023 3 657 81 10.1021/jacsau.2c00572 37006768
Pal I, Dey SG. The role of heme and copper in Alzheimer’s disease and type 2 diabetes mellitus. JACS Au. 2023;3:657–81.37006768 10.1021/jacsau.2c00572
53. Das S Ramachandran AK Halder D Akbar S Ahmed B Joseph A Mechanistic and etiological similarities in diabetes mellitus and Alzheimer’s disease: antidiabetic drugs as optimistic therapeutics in Alzheimer’s disease CNS Neurol Disord Drug Targets 2023 22 973 93 10.2174/1871527321666220629162229 35770411
Das S, Ramachandran AK, Halder D, Akbar S, Ahmed B, Joseph A. Mechanistic and etiological similarities in diabetes mellitus and Alzheimer’s disease: antidiabetic drugs as optimistic therapeutics in Alzheimer’s disease. CNS Neurol Disord Drug Targets. 2023;22:973–93.35770411 10.2174/1871527321666220629162229
54. Sun Y Ma C Sun H Wang H Peng W Zhou Z Metabolism: a novel shared link between diabetes mellitus and Alzheimer’s disease J Diabetes Res 2020 2020 4981814 10.1155/2020/4981814 32083135
Sun Y, Ma C, Sun H, Wang H, Peng W, Zhou Z, et al. Metabolism: a novel shared link between diabetes mellitus and Alzheimer’s disease. J Diabetes Res. 2020;2020:4981814.32083135 10.1155/2020/4981814
55. Sáiz-Vazquez O Puente-Martínez A Pacheco-Bonrostro J Ubillos-Landa S Blood pressure and Alzheimer’s disease: a review of meta-analysis Front Neurol 2022 13 1065335 10.3389/fneur.2022.1065335 36712428
Sáiz-Vazquez O, Puente-Martínez A, Pacheco-Bonrostro J, Ubillos-Landa S. Blood pressure and Alzheimer’s disease: a review of meta-analysis. Front Neurol. 2022;13:1065335.36712428 10.3389/fneur.2022.1065335
56. Sible IJ Nation DA Long-term blood pressure variability across the clinical and biomarker spectrum of Alzheimer’s disease J Alzheimers Dis 2020 77 1655 69 10.3233/JAD-200221 32925032
Sible IJ, Nation DA. Long-term blood pressure variability across the clinical and biomarker spectrum of Alzheimer’s disease. J Alzheimers Dis. 2020;77:1655–69.32925032 10.3233/JAD-200221
57. Daniela M Grigoras C Cuciureanu D Constantinescu V The circadian rhythm of arterial blood pressure in Alzheimer’s disease and vascular dementia Acta Neurol Belg 2023 123 129 37 10.1007/s13760-021-01664-8 34043211
Daniela M, Grigoras C, Cuciureanu D, Constantinescu V. The circadian rhythm of arterial blood pressure in Alzheimer’s disease and vascular dementia. Acta Neurol Belg. 2023;123:129–37.34043211 10.1007/s13760-021-01664-8
58. Vasefi M Ghaboolian-Zare E Abedelwahab H Osu A Environmental toxins and Alzheimer’s disease progression Neurochem Int 2020 141 104852 10.1016/j.neuint.2020.104852 33010393
Vasefi M, Ghaboolian-Zare E, Abedelwahab H, Osu A. Environmental toxins and Alzheimer’s disease progression. Neurochem Int. 2020;141:104852.33010393 10.1016/j.neuint.2020.104852
59. Kumar NN Chan YL Chen H Oliver BG Editorial: effects of environmental toxins on brain health and development Front Mol Neurosci 2023 16 1149776 10.3389/fnmol.2023.1149776 36846566
Kumar NN, Chan YL, Chen H, Oliver BG. Editorial: effects of environmental toxins on brain health and development. Front Mol Neurosci. 2023;16:1149776.36846566 10.3389/fnmol.2023.1149776
60. Falandysz J, Letter to the editor: Comment on “multiannual monitoring (1974-2019) of rare earth elements in wild growing edible mushroom species in Polish forests” by Siwulski et al. 10.1016/j.chemosphere.2020.127173. A recurring question - What are the real concentrations and patterns of REE in mushrooms? Chemosphere. 2023;312:137219.
61. Hou Y Dan X Babbar M Wei Y Hasselbalch SG Croteau DL Ageing as a risk factor for neurodegenerative disease Nat Rev Neurol 2019 15 565 81 10.1038/s41582-019-0244-7 31501588
Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol. 2019;15:565–81.31501588 10.1038/s41582-019-0244-7
62. Nguyen M He T An L Alexander DC Feng J Yeo BTT Predicting Alzheimer’s disease progression using deep recurrent neural networks Neuroimage 2020 222 117203 10.1016/j.neuroimage.2020.117203 32763427
Nguyen M, He T, An L, Alexander DC, Feng J, Yeo BTT. Predicting Alzheimer’s disease progression using deep recurrent neural networks. Neuroimage. 2020;222:117203.32763427 10.1016/j.neuroimage.2020.117203
63. Schermer MHN Preclinical disease or risk factor? Alzheimer’s disease as a case study of changing conceptualizations of disease J Med Philos 2023 48 322 34 10.1093/jmp/jhad009 37202835
Schermer MHN. Preclinical disease or risk factor? Alzheimer’s disease as a case study of changing conceptualizations of disease. J Med Philos. 2023;48:322–34.37202835 10.1093/jmp/jhad009
64. O’Brien J Hayder H Zayed Y Peng C Overview of MicroRNA biogenesis, mechanisms of actions, and circulation Front Endocrinol 2018 9 402 10.3389/fendo.2018.00402
O’Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol. 2018;9:402.10.3389/fendo.2018.00402
65. Wahid F Shehzad A Khan T Kim YY MicroRNAs: synthesis, mechanism, function, and recent clinical trials Biochim Biophys Acta 2010 1803 1231 43 10.1016/j.bbamcr.2010.06.013 20619301
Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta. 2010;1803:1231–43.20619301 10.1016/j.bbamcr.2010.06.013
66. Starega-Roslan J Koscianska E Kozlowski P Krzyzosiak WJ The role of the precursor structure in the biogenesis of microRNA Cell Mol Life Sci 2011 68 2859 71 10.1007/s00018-011-0726-2 21607569
Starega-Roslan J, Koscianska E, Kozlowski P, Krzyzosiak WJ. The role of the precursor structure in the biogenesis of microRNA. Cell Mol Life Sci. 2011;68:2859–71.21607569 10.1007/s00018-011-0726-2
67. Bohnsack MT Czaplinski K Gorlich D Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs RNA 2004 10 185 91 10.1261/rna.5167604 14730017
Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA. 2004;10:185–91.14730017 10.1261/rna.5167604
68. Ambrus AM Frolov MV The diverse roles of RNA helicases in RNAi Cell Cycle 2009 8 3500 5 10.4161/cc.8.21.9887 19823018
Ambrus AM, Frolov MV. The diverse roles of RNA helicases in RNAi. Cell Cycle. 2009;8:3500–5.19823018 10.4161/cc.8.21.9887
69. Treiber T Treiber N Meister G Regulation of microRNA biogenesis and its crosstalk with other cellular pathways Nat Rev Mol Cell Biol 2019 20 5 20 10.1038/s41580-018-0059-1 30228348
Treiber T, Treiber N, Meister G. Regulation of microRNA biogenesis and its crosstalk with other cellular pathways. Nat Rev Mol Cell Biol. 2019;20:5–20.30228348 10.1038/s41580-018-0059-1
70. van den Berg A Mols J Han J RISC-target interaction: cleavage and translational suppression Biochim Biophys Acta 2008 1779 668 77 10.1016/j.bbagrm.2008.07.005 18692607
van den Berg A, Mols J, Han J. RISC-target interaction: cleavage and translational suppression. Biochim Biophys Acta. 2008;1779:668–77.18692607 10.1016/j.bbagrm.2008.07.005
71. Liu CG Song J Zhang YQ Wang PC MicroRNA-193b is a regulator of amyloid precursor protein in the blood and cerebrospinal fluid derived exosomal microRNA-193b is a biomarker of Alzheimer’s disease Mol Med Rep 2014 10 2395 400 10.3892/mmr.2014.2484 25119742
Liu CG, Song J, Zhang YQ, Wang PC. MicroRNA-193b is a regulator of amyloid precursor protein in the blood and cerebrospinal fluid derived exosomal microRNA-193b is a biomarker of Alzheimer’s disease. Mol Med Rep. 2014;10:2395–400.25119742 10.3892/mmr.2014.2484
72. Ørom UA Nielsen FC Lund AH MicroRNA-10a binds the 5’UTR of ribosomal protein mRNAs and enhances their translation Mol Cell 2008 30 460 71 10.1016/j.molcel.2008.05.001 18498749
Ørom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5’UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell. 2008;30:460–71.18498749 10.1016/j.molcel.2008.05.001
73. Bhattacharyya NP Das E Bucha S Das S Choudhury A Regulation of cell cycle associated genes by microRNA and transcription factor Microrna 2016 5 180 200 10.2174/2211536605666161117112251 27855605
Bhattacharyya NP, Das E, Bucha S, Das S, Choudhury A. Regulation of cell cycle associated genes by microRNA and transcription factor. Microrna. 2016;5:180–200.27855605 10.2174/2211536605666161117112251
74. Liu B Shyr Y Cai J Liu Q Interplay between miRNAs and host genes and their role in cancer Brief Funct Genomics 2018 18 255 66 10.1093/bfgp/elz002 30785618
Liu B, Shyr Y, Cai J, Liu Q. Interplay between miRNAs and host genes and their role in cancer. Brief Funct Genomics. 2018;18:255–66.30785618 10.1093/bfgp/elz002
75. Parizi PK Yarahmadi F Tabar HM Hosseini Z Sarli A Kia N MicroRNAs and target molecules in bladder cancer Med Oncol 2020 37 118 10.1007/s12032-020-01435-0 33216248
Parizi PK, Yarahmadi F, Tabar HM, Hosseini Z, Sarli A, Kia N, et al. MicroRNAs and target molecules in bladder cancer. Med Oncol. 2020;37:118.33216248 10.1007/s12032-020-01435-0
76. Colpaert RMW Calore M Epigenetics and microRNAs in cardiovascular diseases Genomics 2021 113 540 51 10.1016/j.ygeno.2020.12.042 33482325
Colpaert RMW, Calore M. Epigenetics and microRNAs in cardiovascular diseases. Genomics. 2021;113:540–51.33482325 10.1016/j.ygeno.2020.12.042
77. Nikolac Perkovic M Videtic Paska A Konjevod M Kouter K Svob Strac D Nedic Erjavec G Epigenetics of Alzheimer’s disease Biomolecules 2021 11 195 10.3390/biom11020195 33573255
Nikolac Perkovic M, Videtic Paska A, Konjevod M, Kouter K, Svob Strac D, Nedic Erjavec G, et al. Epigenetics of Alzheimer’s disease. Biomolecules. 2021;11:195.33573255 10.3390/biom11020195
78. Kumar S Chawla YK Ghosh S Chakraborti A Severity of hepatitis C virus (genotype-3) infection positively correlates with circulating microRNA-122 in patients sera Dis Markers 2014 2014 435476 10.1155/2014/435476 24696531
Kumar S, Chawla YK, Ghosh S, Chakraborti A. Severity of hepatitis C virus (genotype-3) infection positively correlates with circulating microRNA-122 in patients sera. Dis Markers. 2014;2014:435476.24696531 10.1155/2014/435476
79. Kumar S Batra A Kanthaje S Ghosh S Chakraborti A Crosstalk between microRNA-122 and FOX family genes in HepG2 cells Exp Biol Med 2017 242 436 40 10.1177/1535370216681548
Kumar S, Batra A, Kanthaje S, Ghosh S, Chakraborti A. Crosstalk between microRNA-122 and FOX family genes in HepG2 cells. Exp Biol Med. 2017;242:436–40.10.1177/1535370216681548
80. Kumar S Vijayan M Reddy PH MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer’s disease Hum Mol Genet 2017 26 3808 22 10.1093/hmg/ddx267 28934394
Kumar S, Vijayan M, Reddy PH. MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer’s disease. Hum Mol Genet. 2017;26:3808–22.28934394 10.1093/hmg/ddx267
81. Kumar S Reddy PH Are circulating microRNAs peripheral biomarkers for Alzheimer’s disease? Biochim Biophys Acta 2016 1862 1617 27 10.1016/j.bbadis.2016.06.001 27264337
Kumar S, Reddy PH. Are circulating microRNAs peripheral biomarkers for Alzheimer’s disease? Biochim Biophys Acta. 2016;1862:1617–27.27264337 10.1016/j.bbadis.2016.06.001
82. Vijayan M Kumar S Yin X Zafer D Chanana V Cengiz P Identification of novel circulatory microRNA signatures linked to patients with ischemic stroke Hum Mol Genet 2018 27 2318 29 10.1093/hmg/ddy136 29701837
Vijayan M, Kumar S, Yin X, Zafer D, Chanana V, Cengiz P, et al. Identification of novel circulatory microRNA signatures linked to patients with ischemic stroke. Hum Mol Genet. 2018;27:2318–29.29701837 10.1093/hmg/ddy136
83. Zhao Y Jaber VR LeBeauf A Sharfman NM Lukiw WJ microRNA-34a (miRNA-34a) mediated down-regulation of the post-synaptic cytoskeletal element SHANK3 in sporadic Alzheimer’s disease (AD) Front Neurol 2019 10 28 10.3389/fneur.2019.00028 30792687
Zhao Y, Jaber VR, LeBeauf A, Sharfman NM, Lukiw WJ. microRNA-34a (miRNA-34a) mediated down-regulation of the post-synaptic cytoskeletal element SHANK3 in sporadic Alzheimer’s disease (AD). Front Neurol. 2019;10:28.30792687 10.3389/fneur.2019.00028
84. Lukiw WJ microRNA-146a signaling in Alzheimer’s disease (AD) and Prion disease (PrD) Front Neurol 2020 11 462 10.3389/fneur.2020.00462 32670176
Lukiw WJ. microRNA-146a signaling in Alzheimer’s disease (AD) and Prion disease (PrD). Front Neurol. 2020;11:462.32670176 10.3389/fneur.2020.00462
85. Silvestro S Bramanti P Mazzon E Role of miRNAs in Alzheimer’s disease and possible fields of application Int J Mol Sci 2019 20 3979 10.3390/ijms20163979 31443326
Silvestro S, Bramanti P, Mazzon E. Role of miRNAs in Alzheimer’s disease and possible fields of application. Int J Mol Sci. 2019;20:3979.31443326 10.3390/ijms20163979
86. Kenyon CJ The genetics of ageing Nature 2010 464 504 12 10.1038/nature08980 20336132
Kenyon CJ. The genetics of ageing. Nature. 2010;464:504–12.20336132 10.1038/nature08980
87. Smith-Vikos T Slack FJ MicroRNAs and their roles in aging J Cell Sci 2012 125 7 17 10.1242/jcs.099200 22294612
Smith-Vikos T, Slack FJ. MicroRNAs and their roles in aging. J Cell Sci. 2012;125:7–17.22294612 10.1242/jcs.099200
88. Rabin LA Smart CM Amariglio RE Subjective cognitive decline in preclinical Alzheimer’s disease Annu Rev Clin Psychol 2017 13 369 96 10.1146/annurev-clinpsy-032816-045136 28482688
Rabin LA, Smart CM, Amariglio RE. Subjective cognitive decline in preclinical Alzheimer’s disease. Annu Rev Clin Psychol. 2017;13:369–96.28482688 10.1146/annurev-clinpsy-032816-045136
89. Koch G Spampinato D Alzheimer disease and neuroplasticity Handb Clin Neurol 2022 184 473 9 10.1016/B978-0-12-819410-2.00027-8 35034755
Koch G, Spampinato D. Alzheimer disease and neuroplasticity. Handb Clin Neurol. 2022;184:473–9.35034755 10.1016/B978-0-12-819410-2.00027-8
90. Liang WS Reiman EM Valla J Dunckley T Beach TG Grover A Alzheimer’s disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons Proc Natl Acad Sci USA 2008 105 4441 6 10.1073/pnas.0709259105 18332434
Liang WS, Reiman EM, Valla J, Dunckley T, Beach TG, Grover A, et al. Alzheimer’s disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci USA. 2008;105:4441–6.18332434 10.1073/pnas.0709259105
91. Humphries C Kohli MA Rare variants and transcriptomics in Alzheimer disease Curr Genet Med Rep 2014 2 75 84 10.1007/s40142-014-0035-9 25045597
Humphries C, Kohli MA. Rare variants and transcriptomics in Alzheimer disease. Curr Genet Med Rep. 2014;2:75–84.25045597 10.1007/s40142-014-0035-9
92. Kou X Chen D Chen N The regulation of microRNAs in Alzheimer’s disease Front Neurol 2020 11 288 10.3389/fneur.2020.00288 32362867
Kou X, Chen D, Chen N. The regulation of microRNAs in Alzheimer’s disease. Front Neurol. 2020;11:288.32362867 10.3389/fneur.2020.00288
93. Scheltens P Blennow K Breteler MM de Strooper B Frisoni GB Salloway S Alzheimer’s disease Lancet 2016 388 505 17 10.1016/S0140-6736(15)01124-1 26921134
Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer’s disease. Lancet. 2016;388:505–17.26921134 10.1016/S0140-6736(15)01124-1
94. DeTure MA Dickson DW The neuropathological diagnosis of Alzheimer’s disease Mol Neurodegener 2019 14 32 10.1186/s13024-019-0333-5 31375134
DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener. 2019;14:32.31375134 10.1186/s13024-019-0333-5
95. Kandel P Semerci F Mishra R Choi W Bajic A Baluya D Oleic acid is an endogenous ligand of TLX/NR2E1 that triggers hippocampal neurogenesis Proc Natl Acad Sci USA 2022 119 e2023784119 10.1073/pnas.2023784119 35333654
Kandel P, Semerci F, Mishra R, Choi W, Bajic A, Baluya D, et al. Oleic acid is an endogenous ligand of TLX/NR2E1 that triggers hippocampal neurogenesis. Proc Natl Acad Sci USA. 2022;119:e2023784119.35333654 10.1073/pnas.2023784119
96. Sanabria-Castro A Alvarado-Echeverría I Monge-Bonilla C Molecular pathogenesis of Alzheimer’s disease: an update Ann Neurosci 2017 24 46 54 10.1159/000464422 28588356
Sanabria-Castro A, Alvarado-Echeverría I, Monge-Bonilla C. Molecular pathogenesis of Alzheimer’s disease: an update. Ann Neurosci. 2017;24:46–54.28588356 10.1159/000464422
97. Alves da Costa C Sunyach C Pardossi-Piquard R Sévalle J Vincent B Boyer N Presenilin-dependent gamma-secretase-mediated control of p53-associated cell death in Alzheimer’s disease J Neurosci 2006 26 6377 85 10.1523/JNEUROSCI.0651-06.2006 16763046
Alves da Costa C, Sunyach C, Pardossi-Piquard R, Sévalle J, Vincent B, Boyer N, et al. Presenilin-dependent gamma-secretase-mediated control of p53-associated cell death in Alzheimer’s disease. J Neurosci. 2006;26:6377–85.16763046 10.1523/JNEUROSCI.0651-06.2006
98. Hébert SS Horré K Nicolaï L Papadopoulou AS Mandemakers W Silahtaroglu AN Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer’s disease correlates with increased BACE1/beta-secretase expression Proc Natl Acad Sci USA 2008 105 6415 20 10.1073/pnas.0710263105 18434550
Hébert SS, Horré K, Nicolaï L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN, et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer’s disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci USA. 2008;105:6415–20.18434550 10.1073/pnas.0710263105
99. Hébert SS Horré K Nicolaï L Bergmans B Papadopoulou AS Delacourte A MicroRNA regulation of Alzheimer’s Amyloid precursor protein expression Neurobiol Dis 2009 33 422 8 10.1016/j.nbd.2008.11.009 19110058
Hébert SS, Horré K, Nicolaï L, Bergmans B, Papadopoulou AS, Delacourte A, et al. MicroRNA regulation of Alzheimer’s Amyloid precursor protein expression. Neurobiol Dis. 2009;33:422–8.19110058 10.1016/j.nbd.2008.11.009
100. Long JM Lahiri DK MicroRNA-101 downregulates Alzheimer’s amyloid-β precursor protein levels in human cell cultures and is differentially expressed Biochem Biophys Res Commun 2011 404 889 95 10.1016/j.bbrc.2010.12.053 21172309
Long JM, Lahiri DK. MicroRNA-101 downregulates Alzheimer’s amyloid-β precursor protein levels in human cell cultures and is differentially expressed. Biochem Biophys Res Commun. 2011;404:889–95.21172309 10.1016/j.bbrc.2010.12.053
101. Zhang J Wang R Deregulated lncRNA MAGI2-AS3 in Alzheimer’s disease attenuates amyloid-β induced neurotoxicity and neuroinflammation by sponging miR-374b-5p Exp Gerontol 2021 144 111180 10.1016/j.exger.2020.111180 33279663
Zhang J, Wang R. Deregulated lncRNA MAGI2-AS3 in Alzheimer’s disease attenuates amyloid-β induced neurotoxicity and neuroinflammation by sponging miR-374b-5p. Exp Gerontol. 2021;144:111180.33279663 10.1016/j.exger.2020.111180
102. Du W Lei C Dong Y MicroRNA-149 is downregulated in Alzheimer’s disease and inhibits β-amyloid accumulation and ameliorates neuronal viability through targeting BACE1 Genet Mol Biol 2021 44 e20200064 10.1590/1678-4685-gmb-2020-0064 33428703
Du W, Lei C, Dong Y. MicroRNA-149 is downregulated in Alzheimer’s disease and inhibits β-amyloid accumulation and ameliorates neuronal viability through targeting BACE1. Genet Mol Biol. 2021;44:e20200064.33428703 10.1590/1678-4685-gmb-2020-0064
103. An F Gong G Wang Y Bian M Yu L Wei C MiR-124 acts as a target for Alzheimer’s disease by regulating BACE1 Oncotarget 2017 8 114065 71 10.18632/oncotarget.23119 29371969
An F, Gong G, Wang Y, Bian M, Yu L, Wei C. MiR-124 acts as a target for Alzheimer’s disease by regulating BACE1. Oncotarget. 2017;8:114065–71.29371969 10.18632/oncotarget.23119
104. Gong G An F Wang Y Bian M Yu LJ Wei C miR-15b represses BACE1 expression in sporadic Alzheimer’s disease Oncotarget 2017 8 91551 7 10.18632/oncotarget.21177 29207665
Gong G, An F, Wang Y, Bian M, Yu LJ, Wei C. miR-15b represses BACE1 expression in sporadic Alzheimer’s disease. Oncotarget. 2017;8:91551–7.29207665 10.18632/oncotarget.21177
105. Zhong Z Yuan K Tong X Hu J Song Z Zhang G MiR-16 attenuates β-amyloid-induced neurotoxicity through targeting β-site amyloid precursor protein-cleaving enzyme 1 in an Alzheimer’s disease cell model Neuroreport 2018 29 1365 72 10.1097/WNR.0000000000001118 30142113
Zhong Z, Yuan K, Tong X, Hu J, Song Z, Zhang G, et al. MiR-16 attenuates β-amyloid-induced neurotoxicity through targeting β-site amyloid precursor protein-cleaving enzyme 1 in an Alzheimer’s disease cell model. Neuroreport. 2018;29:1365–72.30142113 10.1097/WNR.0000000000001118
106. Li P Xu Y Wang B Huang J Li Q miR-34a-5p and miR-125b-5p attenuate Aβ-induced neurotoxicity through targeting BACE1 J Neurol Sci 2020 413 116793 10.1016/j.jns.2020.116793 32251872
Li P, Xu Y, Wang B, Huang J, Li Q. miR-34a-5p and miR-125b-5p attenuate Aβ-induced neurotoxicity through targeting BACE1. J Neurol Sci. 2020;413:116793.32251872 10.1016/j.jns.2020.116793
107. Cao Y Tan X Lu Q Huang K Tang X He Z MiR-29c-3p may promote the progression of Alzheimer’s disease through BACE1 J Healthc Eng 2021 2021 2031407 10.1155/2021/2031407 34956559
Cao Y, Tan X, Lu Q, Huang K, Tang X, He Z. MiR-29c-3p may promote the progression of Alzheimer’s disease through BACE1. J Healthc Eng. 2021;2021:2031407.34956559 10.1155/2021/2031407
108. Tan X Luo Y Pi D Xia L Li Z Tu Q MiR-340 reduces the accumulation of Amyloid-β through targeting BACE1 (β-site amyloid precursor protein cleaving enzyme 1) in Alzheimer’s disease Curr Neurovasc Res 2020 17 86 92 10.2174/1567202617666200117103931 31957613
Tan X, Luo Y, Pi D, Xia L, Li Z, Tu Q. MiR-340 reduces the accumulation of Amyloid-β through targeting BACE1 (β-site amyloid precursor protein cleaving enzyme 1) in Alzheimer’s disease. Curr Neurovasc Res. 2020;17:86–92.31957613 10.2174/1567202617666200117103931
109. Ji Q Wang X Cai J Du X Sun H Zhang N MiR-22-3p regulates amyloid β deposit in mice model of Alzheimer’s disease by targeting mitogen-activated protein kinase 14 Curr Neurovasc Res 2019 16 473 80 10.2174/1567202616666191111124516 31713484
Ji Q, Wang X, Cai J, Du X, Sun H, Zhang N. MiR-22-3p regulates amyloid β deposit in mice model of Alzheimer’s disease by targeting mitogen-activated protein kinase 14. Curr Neurovasc Res. 2019;16:473–80.31713484 10.2174/1567202616666191111124516
110. Delay C Mandemakers W Hébert SS MicroRNAs in Alzheimer’s disease Neurobiol Dis 2012 46 285 90 10.1016/j.nbd.2012.01.003 22285895
Delay C, Mandemakers W, Hébert SS. MicroRNAs in Alzheimer’s disease. Neurobiol Dis. 2012;46:285–90.22285895 10.1016/j.nbd.2012.01.003
111. Zhu HC Wang LM Wang M Song B Tan S Teng JF MicroRNA-195 downregulates Alzheimer’s disease amyloid-β production by targeting BACE1 Brain Res Bull 2012 88 596 601 10.1016/j.brainresbull.2012.05.018 22721728
Zhu HC, Wang LM, Wang M, Song B, Tan S, Teng JF, et al. MicroRNA-195 downregulates Alzheimer’s disease amyloid-β production by targeting BACE1. Brain Res Bull. 2012;88:596–601.22721728 10.1016/j.brainresbull.2012.05.018
112. Kim J Yoon H Chung DE Brown JL Belmonte KC Kim J miR-186 is decreased in aged brain and suppresses BACE1 expression J Neurochem 2016 137 436 45 10.1111/jnc.13507 26710318
Kim J, Yoon H, Chung DE, Brown JL, Belmonte KC, Kim J. miR-186 is decreased in aged brain and suppresses BACE1 expression. J Neurochem. 2016;137:436–45.26710318 10.1111/jnc.13507
113. Patel N Hoang D Miller N Ansaloni S Huang Q Rogers JT MicroRNAs can regulate human APP levels Mol Neurodegener 2008 3 10 10.1186/1750-1326-3-10 18684319
Patel N, Hoang D, Miller N, Ansaloni S, Huang Q, Rogers JT, et al. MicroRNAs can regulate human APP levels. Mol Neurodegener. 2008;3:10.18684319 10.1186/1750-1326-3-10
114. Liu W Liu C Zhu J Shu P Yin B Gong Y MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer’s-associated pathogenesis in SAMP8 mice Neurobiol Aging 2012 33 522 34 10.1016/j.neurobiolaging.2010.04.034 20619502
Liu W, Liu C, Zhu J, Shu P, Yin B, Gong Y, et al. MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer’s-associated pathogenesis in SAMP8 mice. Neurobiol Aging. 2012;33:522–34.20619502 10.1016/j.neurobiolaging.2010.04.034
115. Yaksh TL TRPV1 expression regulation… A further step in defining its biology: commentary for K. Zavala et al. “The anticancer antibiotic mithramycin-A inhibits TRPV1 expression in dorsal root ganglion neurons” [Neurosci. Lett. (2014) doi:10.1016/j.neulet.2014.01.021] Neurosci Lett 2014 578 209 10 10.1016/j.neulet.2014.04.022 24769421
Yaksh TL. TRPV1 expression regulation… A further step in defining its biology: commentary for K. Zavala et al. “The anticancer antibiotic mithramycin-A inhibits TRPV1 expression in dorsal root ganglion neurons” [Neurosci. Lett. (2014) doi:10.1016/j.neulet.2014.01.021]. Neurosci Lett. 2014;578:209–10.24769421 10.1016/j.neulet.2014.04.022
116. Tiribuzi R Crispoltoni L Porcellati S Di Lullo M Florenzano F Pirro M miR128 up-regulation correlates with impaired amyloid β(1-42) degradation in monocytes from patients with sporadic Alzheimer’s disease Neurobiol Aging 2014 35 345 56 10.1016/j.neurobiolaging.2013.08.003 24064186
Tiribuzi R, Crispoltoni L, Porcellati S, Di Lullo M, Florenzano F, Pirro M, et al. miR128 up-regulation correlates with impaired amyloid β(1-42) degradation in monocytes from patients with sporadic Alzheimer’s disease. Neurobiol Aging. 2014;35:345–56.24064186 10.1016/j.neurobiolaging.2013.08.003
117. Goedert M Spillantini MG Jakes R Rutherford D Crowther RA Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease Neuron 1989 3 519 26 10.1016/0896-6273(89)90210-9 2484340
Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron. 1989;3:519–26.2484340 10.1016/0896-6273(89)90210-9
118. Querfurth HW LaFerla FM Alzheimer’s disease N Engl J Med 2010 362 329 44 10.1056/NEJMra0909142 20107219
Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010;362:329–44.20107219 10.1056/NEJMra0909142
119. Aamodt EJ Williams RC Jr Microtubule-associated proteins connect microtubules and neurofilaments in vitro Biochemistry 1984 23 6023 31 10.1021/bi00320a019 6543144
Aamodt EJ, Williams RC Jr. Microtubule-associated proteins connect microtubules and neurofilaments in vitro. Biochemistry. 1984;23:6023–31.6543144 10.1021/bi00320a019
120. González-Billault C Engelke M Jiménez-Mateos EM Wandosell F Cáceres A Avila J Participation of structural microtubule-associated proteins (MAPs) in the development of neuronal polarity J Neurosci Res 2002 67 713 9 10.1002/jnr.10161 11891784
González-Billault C, Engelke M, Jiménez-Mateos EM, Wandosell F, Cáceres A, Avila J. Participation of structural microtubule-associated proteins (MAPs) in the development of neuronal polarity. J Neurosci Res. 2002;67:713–9.11891784 10.1002/jnr.10161
121. Iqbal K Liu F Gong CX Grundke-Iqbal I Tau in Alzheimer disease and related tauopathies Curr Alzheimer Res 2010 7 656 64 10.2174/156720510793611592 20678074
Iqbal K, Liu F, Gong CX, Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res. 2010;7:656–64.20678074 10.2174/156720510793611592
122. Landgraf P Rusu M Sheridan R Sewer A Iovino N Aravin A A mammalian microRNA expression atlas based on small RNA library sequencing Cell 2007 129 1401 14 10.1016/j.cell.2007.04.040 17604727
Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007;129:1401–14.17604727 10.1016/j.cell.2007.04.040
123. Hansen KF Sakamoto K Aten S Price KH Loeser J Hesse AM Targeted deletion of miR-132/-212 impairs memory and alters the hippocampal transcriptome Learn Mem 2016 23 61 71 10.1101/lm.039578.115 26773099
Hansen KF, Sakamoto K, Aten S, Price KH, Loeser J, Hesse AM, et al. Targeted deletion of miR-132/-212 impairs memory and alters the hippocampal transcriptome. Learn Mem. 2016;23:61–71.26773099 10.1101/lm.039578.115
124. Hernandez-Rapp J Smith PY Filali M Goupil C Planel E Magill ST Memory formation and retention are affected in adult miR-132/212 knockout mice Behav Brain Res 2015 287 15 26 10.1016/j.bbr.2015.03.032 25813747
Hernandez-Rapp J, Smith PY, Filali M, Goupil C, Planel E, Magill ST, et al. Memory formation and retention are affected in adult miR-132/212 knockout mice. Behav Brain Res. 2015;287:15–26.25813747 10.1016/j.bbr.2015.03.032
125. Liu DY Zhang L MicroRNA-132 promotes neurons cell apoptosis and activates Tau phosphorylation by targeting GTDC-1 in Alzheimer’s disease Eur Rev Med Pharmacol Sci 2019 23 8523 32 31646584
Liu DY, Zhang L. MicroRNA-132 promotes neurons cell apoptosis and activates Tau phosphorylation by targeting GTDC-1 in Alzheimer’s disease. Eur Rev Med Pharmacol Sci. 2019;23:8523–32.31646584
126. Yuan J Wu Y Li L Liu C MicroRNA-425-5p promotes tau phosphorylation and cell apoptosis in Alzheimer’s disease by targeting heat shock protein B8 J Neural Transm 2020 127 339 46 10.1007/s00702-019-02134-5 31919655
Yuan J, Wu Y, Li L, Liu C. MicroRNA-425-5p promotes tau phosphorylation and cell apoptosis in Alzheimer’s disease by targeting heat shock protein B8. J Neural Transm. 2020;127:339–46.31919655 10.1007/s00702-019-02134-5
127. Kang Q Xiang Y Li D Liang J Zhang X Zhou F MiR-124-3p attenuates hyperphosphorylation of Tau protein-induced apoptosis via caveolin-1-PI3K/Akt/GSK3β pathway in N2a/APP695swe cells Oncotarget 2017 8 24314 26 10.18632/oncotarget.15149 28186985
Kang Q, Xiang Y, Li D, Liang J, Zhang X, Zhou F, et al. MiR-124-3p attenuates hyperphosphorylation of Tau protein-induced apoptosis via caveolin-1-PI3K/Akt/GSK3β pathway in N2a/APP695swe cells. Oncotarget. 2017;8:24314–26.28186985 10.18632/oncotarget.15149
128. Mezache L Mikhail M Garofalo M Nuovo GJ Reduced miR-512 and the elevated expression of its targets cFLIP and MCL1 localize to neurons with hyperphosphorylated tau protein in Alzheimer disease Appl Immunohistochem Mol Morphol 2015 23 615 23 10.1097/PAI.0000000000000147 26258756
Mezache L, Mikhail M, Garofalo M, Nuovo GJ. Reduced miR-512 and the elevated expression of its targets cFLIP and MCL1 localize to neurons with hyperphosphorylated tau protein in Alzheimer disease. Appl Immunohistochem Mol Morphol. 2015;23:615–23.26258756 10.1097/PAI.0000000000000147
129. Nagaraj S Want A Laskowska-Kaszub K Fesiuk A Vaz S Logarinho E Candidate Alzheimer’s disease biomarker miR-483-5p lowers TAU phosphorylation by direct ERK1/2 repression Int J Mol Sci 2021 22 3653 10.3390/ijms22073653 33915734
Nagaraj S, Want A, Laskowska-Kaszub K, Fesiuk A, Vaz S, Logarinho E, et al. Candidate Alzheimer’s disease biomarker miR-483-5p lowers TAU phosphorylation by direct ERK1/2 repression. Int J Mol Sci. 2021;22:3653.33915734 10.3390/ijms22073653
130. Zhao H Feng L Zhong W Zhen H Chi Q Wang X Hyperphosphorylation of Tau due to the interference of protein phosphatase methylesterase-1 overexpression by MiR-125b-5p in melatonin receptor knockout mice Int J Mol Sci 2021 22 11850 10.3390/ijms222111850 34769281
Zhao H, Feng L, Zhong W, Zhen H, Chi Q, Wang X. Hyperphosphorylation of Tau due to the interference of protein phosphatase methylesterase-1 overexpression by MiR-125b-5p in melatonin receptor knockout mice. Int J Mol Sci. 2021;22:11850.34769281 10.3390/ijms222111850
131. McGeer PL McGeer EG Inflammation and the degenerative diseases of aging Ann N Y Acad Sci 2004 1035 104 16 10.1196/annals.1332.007 15681803
McGeer PL, McGeer EG. Inflammation and the degenerative diseases of aging. Ann N Y Acad Sci. 2004;1035:104–16.15681803 10.1196/annals.1332.007
132. Kinney JW Bemiller SM Murtishaw AS Leisgang AM Salazar AM Lamb BT Inflammation as a central mechanism in Alzheimer’s disease Alzheimers Dement 2018 4 575 90
Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dement. 2018;4:575–90.
133. Kwon HS Koh SH Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes Transl Neurodegener 2020 9 42 10.1186/s40035-020-00221-2 33239064
Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener. 2020;9:42.33239064 10.1186/s40035-020-00221-2
134. Akiyama H Barger S Barnum S Bradt B Bauer J Cole GM Inflammation and Alzheimer’s disease Neurobiol Aging 2000 21 383 421 10.1016/S0197-4580(00)00124-X 10858586
Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer’s disease. Neurobiol Aging. 2000;21:383–421.10858586 10.1016/S0197-4580(00)00124-X
135. Kitazawa M Yamasaki TR LaFerla FM Microglia as a potential bridge between the amyloid beta-peptide and tau Ann N Y Acad Sci 2004 1035 85 103 10.1196/annals.1332.006 15681802
Kitazawa M, Yamasaki TR, LaFerla FM. Microglia as a potential bridge between the amyloid beta-peptide and tau. Ann N Y Acad Sci. 2004;1035:85–103.15681802 10.1196/annals.1332.006
136. Colombo E Farina C Astrocytes: key regulators of neuroinflammation Trends Immunol 2016 37 608 20 10.1016/j.it.2016.06.006 27443914
Colombo E, Farina C. Astrocytes: key regulators of neuroinflammation. Trends Immunol. 2016;37:608–20.27443914 10.1016/j.it.2016.06.006
137. Saijo K Winner B Carson CT Collier JG Boyer L Rosenfeld MG A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death Cell 2009 137 47 59 10.1016/j.cell.2009.01.038 19345186
Saijo K, Winner B, Carson CT, Collier JG, Boyer L, Rosenfeld MG, et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell. 2009;137:47–59.19345186 10.1016/j.cell.2009.01.038
138. Liddelow SA Guttenplan KA Clarke LE Bennett FC Bohlen CJ Schirmer L Neurotoxic reactive astrocytes are induced by activated microglia Nature 2017 541 481 7 10.1038/nature21029 28099414
Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481–7.28099414 10.1038/nature21029
139. Rothstein JD Dykes-Hoberg M Pardo CA Bristol LA Jin L Kuncl RW Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate Neuron 1996 16 675 86 10.1016/S0896-6273(00)80086-0 8785064
Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RW, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron. 1996;16:675–86.8785064 10.1016/S0896-6273(00)80086-0
140. Kellner V Menkes-Caspi N Beker S Stern EA Amyloid-β alters ongoing neuronal activity and excitability in the frontal cortex Neurobiol Aging 2014 35 1982 91 10.1016/j.neurobiolaging.2014.04.001 24792906
Kellner V, Menkes-Caspi N, Beker S, Stern EA. Amyloid-β alters ongoing neuronal activity and excitability in the frontal cortex. Neurobiol Aging. 2014;35:1982–91.24792906 10.1016/j.neurobiolaging.2014.04.001
141. Andersen JV Schousboe A Verkhratsky A Astrocyte energy and neurotransmitter metabolism in Alzheimer’s disease: Integration of the glutamate/GABA-glutamine cycle Prog Neurobiol 2022 217 102331 10.1016/j.pneurobio.2022.102331 35872221
Andersen JV, Schousboe A, Verkhratsky A. Astrocyte energy and neurotransmitter metabolism in Alzheimer’s disease: Integration of the glutamate/GABA-glutamine cycle. Prog Neurobiol. 2022;217:102331.35872221 10.1016/j.pneurobio.2022.102331
142. Pomilio C Gorojod RM Riudavets M Vinuesa A Presa J Gregosa A Microglial autophagy is impaired by prolonged exposure to β-amyloid peptides: evidence from experimental models and Alzheimer’s disease patients Geroscience 2020 42 613 32 10.1007/s11357-020-00161-9 31975051
Pomilio C, Gorojod RM, Riudavets M, Vinuesa A, Presa J, Gregosa A, et al. Microglial autophagy is impaired by prolonged exposure to β-amyloid peptides: evidence from experimental models and Alzheimer’s disease patients. Geroscience. 2020;42:613–32.31975051 10.1007/s11357-020-00161-9
143. Jia R Guardia CM Pu J Chen Y Bonifacino JS BORC coordinates encounter and fusion of lysosomes with autophagosomes Autophagy 2017 13 1648 63 10.1080/15548627.2017.1343768 28825857
Jia R, Guardia CM, Pu J, Chen Y, Bonifacino JS. BORC coordinates encounter and fusion of lysosomes with autophagosomes. Autophagy. 2017;13:1648–63.28825857 10.1080/15548627.2017.1343768
144. Qian M Fang X Wang X Autophagy and inflammation Clin Transl Med 2017 6 24 10.1186/s40169-017-0154-5 28748360
Qian M, Fang X, Wang X. Autophagy and inflammation. Clin Transl Med. 2017;6:24.28748360 10.1186/s40169-017-0154-5
145. Nixon RA Autophagy, amyloidogenesis and Alzheimer disease J Cell Sci 2007 120 4081 91 10.1242/jcs.019265 18032783
Nixon RA. Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci. 2007;120:4081–91.18032783 10.1242/jcs.019265
146. Chun H Marriott I Lee CJ Cho H Elucidating the interactive roles of glia in Alzheimer’s disease using established and newly developed experimental models Front Neurol 2018 9 797 10.3389/fneur.2018.00797 30319529
Chun H, Marriott I, Lee CJ, Cho H. Elucidating the interactive roles of glia in Alzheimer’s disease using established and newly developed experimental models. Front Neurol. 2018;9:797.30319529 10.3389/fneur.2018.00797
147. Ginhoux F Lim S Hoeffel G Low D Huber T Origin and differentiation of microglia Front Cell Neurosci 2013 7 45 10.3389/fncel.2013.00045 23616747
Ginhoux F, Lim S, Hoeffel G, Low D, Huber T. Origin and differentiation of microglia. Front Cell Neurosci. 2013;7:45.23616747 10.3389/fncel.2013.00045
148. Wolf SA Boddeke HW Kettenmann H Microglia in physiology and disease Annu Rev Physiol 2017 79 619 43 10.1146/annurev-physiol-022516-034406 27959620
Wolf SA, Boddeke HW, Kettenmann H. Microglia in physiology and disease. Annu Rev Physiol. 2017;79:619–43.27959620 10.1146/annurev-physiol-022516-034406
149. Jin JJ Kim HD Maxwell JA Li L Fukuchi K Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer’s disease J Neuroinflammation 2008 5 23 10.1186/1742-2094-5-23 18510752
Jin JJ, Kim HD, Maxwell JA, Li L, Fukuchi K. Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer’s disease. J Neuroinflammation. 2008;5:23.18510752 10.1186/1742-2094-5-23
150. Tahara K Kim HD Jin JJ Maxwell JA Li L Fukuchi K Role of toll-like receptor signalling in Abeta uptake and clearance Brain 2006 129 3006 19 10.1093/brain/awl249 16984903
Tahara K, Kim HD, Jin JJ, Maxwell JA, Li L, Fukuchi K. Role of toll-like receptor signalling in Abeta uptake and clearance. Brain. 2006;129:3006–19.16984903 10.1093/brain/awl249
151. Yan SD Chen X Fu J Chen M Zhu H Roher A RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease Nature 1996 382 685 91 10.1038/382685a0 8751438
Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. Nature. 1996;382:685–91.8751438 10.1038/382685a0
152. Heneka MT Kummer MP Stutz A Delekate A Schwartz S Vieira-Saecker A NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice Nature 2013 493 674 8 10.1038/nature11729 23254930
Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493:674–8.23254930 10.1038/nature11729
153. Takeuchi O Akira S Pattern recognition receptors and inflammation Cell 2010 140 805 20 10.1016/j.cell.2010.01.022 20303872
Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140:805–20.20303872 10.1016/j.cell.2010.01.022
154. Kriegstein A Alvarez-Buylla A The glial nature of embryonic and adult neural stem cells Annu Rev Neurosci 2009 32 149 84 10.1146/annurev.neuro.051508.135600 19555289
Kriegstein A, Alvarez-Buylla A. The glial nature of embryonic and adult neural stem cells. Annu Rev Neurosci. 2009;32:149–84.19555289 10.1146/annurev.neuro.051508.135600
155. Sofroniew MV Molecular dissection of reactive astrogliosis and glial scar formation Trends Neurosci 2009 32 638 47 10.1016/j.tins.2009.08.002 19782411
Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 2009;32:638–47.19782411 10.1016/j.tins.2009.08.002
156. Farhy-Tselnicker I Allen NJ Astrocytes, neurons, synapses: a tripartite view on cortical circuit development Neural Dev 2018 13 7 10.1186/s13064-018-0104-y 29712572
Farhy-Tselnicker I, Allen NJ. Astrocytes, neurons, synapses: a tripartite view on cortical circuit development. Neural Dev. 2018;13:7.29712572 10.1186/s13064-018-0104-y
157. Colombo E Cordiglieri C Melli G Newcombe J Krumbholz M Parada LF Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide production and neurodegeneration J Exp Med 2012 209 521 35 10.1084/jem.20110698 22393127
Colombo E, Cordiglieri C, Melli G, Newcombe J, Krumbholz M, Parada LF, et al. Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide production and neurodegeneration. J Exp Med. 2012;209:521–35.22393127 10.1084/jem.20110698
158. Singh A Abraham WC Astrocytes and synaptic plasticity in health and disease Exp Brain Res 2017 235 1645 55 10.1007/s00221-017-4928-1 28299411
Singh A, Abraham WC. Astrocytes and synaptic plasticity in health and disease. Exp Brain Res. 2017;235:1645–55.28299411 10.1007/s00221-017-4928-1
159. Paudel YN Angelopoulou E Piperi C Othman I Aamir K Shaikh MF Impact of HMGB1, RAGE, and TLR4 in Alzheimer’s disease (AD): from risk factors to therapeutic targeting Cells 2020 9 383 10.3390/cells9020383 32046119
Paudel YN, Angelopoulou E, Piperi C, Othman I, Aamir K, Shaikh MF. Impact of HMGB1, RAGE, and TLR4 in Alzheimer’s disease (AD): from risk factors to therapeutic targeting. Cells. 2020;9:383.32046119 10.3390/cells9020383
160. Liang C Zou T Zhang M Fan W Zhang T Jiang Y MicroRNA-146a switches microglial phenotypes to resist the pathological processes and cognitive degradation of Alzheimer’s disease Theranostics 2021 11 4103 21 10.7150/thno.53418 33754051
Liang C, Zou T, Zhang M, Fan W, Zhang T, Jiang Y, et al. MicroRNA-146a switches microglial phenotypes to resist the pathological processes and cognitive degradation of Alzheimer’s disease. Theranostics. 2021;11:4103–21.33754051 10.7150/thno.53418
161. Huang Y Lin X Lin X MiR-146a-5p contributes to microglial polarization transitions associated With AGEs Mol Neurobiol 2023 60 3020 33 10.1007/s12035-023-03252-8 36780120
Huang Y, Lin X, Lin X. MiR-146a-5p contributes to microglial polarization transitions associated With AGEs. Mol Neurobiol. 2023;60:3020–33.36780120 10.1007/s12035-023-03252-8
162. Redis RS Calin S Yang Y You MJ Calin GA Cell-to-cell miRNA transfer: from body homeostasis to therapy Pharmacol Ther 2012 136 169 74 10.1016/j.pharmthera.2012.08.003 22903157
Redis RS, Calin S, Yang Y, You MJ, Calin GA. Cell-to-cell miRNA transfer: from body homeostasis to therapy. Pharmacol Ther. 2012;136:169–74.22903157 10.1016/j.pharmthera.2012.08.003
163. Zhang G Liu Y Xu L Sha C Zhang H Xu W Resveratrol alleviates lipopolysaccharide-induced inflammation in PC-12 cells and in rat model BMC Biotechnol 2019 19 10 10.1186/s12896-019-0502-1 30691440
Zhang G, Liu Y, Xu L, Sha C, Zhang H, Xu W. Resveratrol alleviates lipopolysaccharide-induced inflammation in PC-12 cells and in rat model. BMC Biotechnol. 2019;19:10.30691440 10.1186/s12896-019-0502-1
164. Rastegar-Moghaddam SH Ebrahimzadeh-Bideskan A Shahba S Malvandi AM Mohammadipour A Roles of the miR-155 in neuroinflammation and neurological disorders: a potent biological and therapeutic target Cell Mol Neurobiol 2023 43 455 67 10.1007/s10571-022-01200-z 35107690
Rastegar-Moghaddam SH, Ebrahimzadeh-Bideskan A, Shahba S, Malvandi AM, Mohammadipour A. Roles of the miR-155 in neuroinflammation and neurological disorders: a potent biological and therapeutic target. Cell Mol Neurobiol. 2023;43:455–67.35107690 10.1007/s10571-022-01200-z
165. Yin Z Herron S Silveira S Kleemann K Gauthier C Mallah D Identification of a protective microglial state mediated by miR-155 and interferon-γ signaling in a mouse model of Alzheimer’s disease Nat Neurosci 2023 26 1196 207 10.1038/s41593-023-01355-y 37291336
Yin Z, Herron S, Silveira S, Kleemann K, Gauthier C, Mallah D, et al. Identification of a protective microglial state mediated by miR-155 and interferon-γ signaling in a mouse model of Alzheimer’s disease. Nat Neurosci. 2023;26:1196–207.37291336 10.1038/s41593-023-01355-y
166. Song J Lee JE miR-155 is involved in Alzheimer’s disease by regulating T lymphocyte function Front Aging Neurosci 2015 7 61 10.3389/fnagi.2015.00061 25983691
Song J, Lee JE. miR-155 is involved in Alzheimer’s disease by regulating T lymphocyte function. Front Aging Neurosci. 2015;7:61.25983691 10.3389/fnagi.2015.00061
167. Mattson MP Late-onset dementia: a mosaic of prototypical pathologies modifiable by diet and lifestyle NPJ Aging Mech Dis 2015 1 15003- 10.1038/npjamd.2015.3 28642821
Mattson MP. Late-onset dementia: a mosaic of prototypical pathologies modifiable by diet and lifestyle. NPJ Aging Mech Dis. 2015;1:15003-.28642821 10.1038/npjamd.2015.3
168. Oliver DMA Reddy PH Molecular basis of Alzheimer’s disease: focus on mitochondria J Alzheimers Dis 2019 72 S95 s116 10.3233/JAD-190048 30932888
Oliver DMA, Reddy PH. Molecular basis of Alzheimer’s disease: focus on mitochondria. J Alzheimers Dis. 2019;72:S95–s116.30932888 10.3233/JAD-190048
169. Wei Z Li X Li X Liu Q Cheng Y Oxidative stress in Parkinson’s disease: a systematic review and meta-analysis Front Mol Neurosci 2018 11 236 10.3389/fnmol.2018.00236 30026688
Wei Z, Li X, Li X, Liu Q, Cheng Y. Oxidative stress in Parkinson’s disease: a systematic review and meta-analysis. Front Mol Neurosci. 2018;11:236.30026688 10.3389/fnmol.2018.00236
170. Nunomura A Hofer T Moreira PI Castellani RJ Smith MA Perry G RNA oxidation in Alzheimer disease and related neurodegenerative disorders Acta Neuropathol 2009 118 151 66 10.1007/s00401-009-0508-1 19271225
Nunomura A, Hofer T, Moreira PI, Castellani RJ, Smith MA, Perry G. RNA oxidation in Alzheimer disease and related neurodegenerative disorders. Acta Neuropathol. 2009;118:151–66.19271225 10.1007/s00401-009-0508-1
171. Nunomura A Moreira PI Castellani RJ Lee HG Zhu X Smith MA Oxidative damage to RNA in aging and neurodegenerative disorders Neurotox Res 2012 22 231 48 10.1007/s12640-012-9331-x 22669748
Nunomura A, Moreira PI, Castellani RJ, Lee HG, Zhu X, Smith MA, et al. Oxidative damage to RNA in aging and neurodegenerative disorders. Neurotox Res. 2012;22:231–48.22669748 10.1007/s12640-012-9331-x
172. Singh A Kukreti R Saso L Kukreti S Oxidative stress: a key modulator in neurodegenerative diseases Molecules 2019 24 1583 10.3390/molecules24081583 31013638
Singh A, Kukreti R, Saso L, Kukreti S. Oxidative stress: a key modulator in neurodegenerative diseases. Molecules. 2019;24:1583.31013638 10.3390/molecules24081583
173. Teleanu DM Niculescu AG Lungu II Radu CI Vladâcenco O Roza E An overview of oxidative stress, neuroinflammation, and neurodegenerative diseases Int J Mol Sci 2022 23 5938 10.3390/ijms23115938 35682615
Teleanu DM, Niculescu AG, Lungu II, Radu CI, Vladâcenco O, Roza E, et al. An overview of oxidative stress, neuroinflammation, and neurodegenerative diseases. Int J Mol Sci. 2022;23:5938.35682615 10.3390/ijms23115938
174. Birnbaum JH Wanner D Gietl AF Saake A Kündig TM Hock C Oxidative stress and altered mitochondrial protein expression in the absence of amyloid-β and tau pathology in iPSC-derived neurons from sporadic Alzheimer’s disease patients Stem Cell Res 2018 27 121 30 10.1016/j.scr.2018.01.019 29414602
Birnbaum JH, Wanner D, Gietl AF, Saake A, Kündig TM, Hock C, et al. Oxidative stress and altered mitochondrial protein expression in the absence of amyloid-β and tau pathology in iPSC-derived neurons from sporadic Alzheimer’s disease patients. Stem Cell Res. 2018;27:121–30.29414602 10.1016/j.scr.2018.01.019
175. Jiao Y Kong L Yao Y Li S Tao Z Yan Y Osthole decreases beta amyloid levels through up-regulation of miR-107 in Alzheimer’s disease Neuropharmacology 2016 108 332 44 10.1016/j.neuropharm.2016.04.046 27143098
Jiao Y, Kong L, Yao Y, Li S, Tao Z, Yan Y, et al. Osthole decreases beta amyloid levels through up-regulation of miR-107 in Alzheimer’s disease. Neuropharmacology. 2016;108:332–44.27143098 10.1016/j.neuropharm.2016.04.046
176. Jin Y Tu Q Liu M MicroRNA‑125b regulates Alzheimer’s disease through SphK1 regulation Mol Med Rep 2018 18 2373 80 29901156
Jin Y, Tu Q, Liu M. MicroRNA‑125b regulates Alzheimer’s disease through SphK1 regulation. Mol Med Rep. 2018;18:2373–80.29901156
177. Zhang L Dong H Si Y Wu N Cao H Mei B miR-125b promotes tau phosphorylation by targeting the neural cell adhesion molecule in neuropathological progression Neurobiol Aging 2019 73 41 49 10.1016/j.neurobiolaging.2018.09.011 30316051
Zhang L, Dong H, Si Y, Wu N, Cao H, Mei B, et al. miR-125b promotes tau phosphorylation by targeting the neural cell adhesion molecule in neuropathological progression. Neurobiol Aging. 2019;73:41–49.30316051 10.1016/j.neurobiolaging.2018.09.011
178. Ji G Lv K Chen H Wang T Wang Y Zhao D MiR-146a regulates SOD2 expression in H2O2 stimulated PC12 cells PLoS ONE 2013 8 e69351 10.1371/journal.pone.0069351 23935993
Ji G, Lv K, Chen H, Wang T, Wang Y, Zhao D, et al. MiR-146a regulates SOD2 expression in H2O2 stimulated PC12 cells. PLoS ONE. 2013;8:e69351.23935993 10.1371/journal.pone.0069351
179. Lukiw WJ Zhao Y Cui JG An NF-kappaB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells J Biol Chem 2008 283 31315 22 10.1074/jbc.M805371200 18801740
Lukiw WJ, Zhao Y, Cui JG. An NF-kappaB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J Biol Chem. 2008;283:31315–22.18801740 10.1074/jbc.M805371200
180. Wang G Huang Y Wang LL Zhang YF Xu J Zhou Y MicroRNA-146a suppresses ROCK1 allowing hyperphosphorylation of tau in Alzheimer’s disease Sci Rep 2016 6 26697 10.1038/srep26697 27221467
Wang G, Huang Y, Wang LL, Zhang YF, Xu J, Zhou Y, et al. MicroRNA-146a suppresses ROCK1 allowing hyperphosphorylation of tau in Alzheimer’s disease. Sci Rep. 2016;6:26697.27221467 10.1038/srep26697
181. Xu S Zhang R Niu J Cui D Xie B Zhang B Oxidative stress mediated-alterations of the microRNA expression profile in mouse hippocampal neurons Int J Mol Sci 2012 13 16945 60 10.3390/ijms131216945 23443129
Xu S, Zhang R, Niu J, Cui D, Xie B, Zhang B, et al. Oxidative stress mediated-alterations of the microRNA expression profile in mouse hippocampal neurons. Int J Mol Sci. 2012;13:16945–60.23443129 10.3390/ijms131216945
182. Higaki S Muramatsu M Matsuda A Matsumoto K Satoh JI Michikawa M Defensive effect of microRNA-200b/c against amyloid-beta peptide-induced toxicity in Alzheimer’s disease models PLoS ONE 2018 13 e0196929 10.1371/journal.pone.0196929 29738527
Higaki S, Muramatsu M, Matsuda A, Matsumoto K, Satoh JI, Michikawa M, et al. Defensive effect of microRNA-200b/c against amyloid-beta peptide-induced toxicity in Alzheimer’s disease models. PLoS ONE. 2018;13:e0196929.29738527 10.1371/journal.pone.0196929
183. Wu Q Ye X Xiong Y Zhu H Miao J Zhang W The protective role of microRNA-200c in Alzheimer’s disease pathologies is induced by beta amyloid-triggered endoplasmic reticulum stress Front Mol Neurosci 2016 9 140 10.3389/fnmol.2016.00140 28008308
Wu Q, Ye X, Xiong Y, Zhu H, Miao J, Zhang W, et al. The protective role of microRNA-200c in Alzheimer’s disease pathologies is induced by beta amyloid-triggered endoplasmic reticulum stress. Front Mol Neurosci. 2016;9:140.28008308 10.3389/fnmol.2016.00140
184. Ballard C Gauthier S Corbett A Brayne C Aarsland D Jones E Alzheimer’s disease Lancet 2011 377 1019 31 10.1016/S0140-6736(10)61349-9 21371747
Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer’s disease. Lancet. 2011;377:1019–31.21371747 10.1016/S0140-6736(10)61349-9
185. Hardy J Selkoe DJ The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics Science 2002 297 353 6 10.1126/science.1072994 12130773
Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–6.12130773 10.1126/science.1072994
186. Polanco JC Li C Bodea LG Martinez-Marmol R Meunier FA Götz J Amyloid-β and tau complexity - towards improved biomarkers and targeted therapies Nat Rev Neurol 2018 14 22 39 10.1038/nrneurol.2017.162 29242522
Polanco JC, Li C, Bodea LG, Martinez-Marmol R, Meunier FA, Götz J. Amyloid-β and tau complexity - towards improved biomarkers and targeted therapies. Nat Rev Neurol. 2018;14:22–39.29242522 10.1038/nrneurol.2017.162
187. Selkoe DJ Alzheimer’s disease is a synaptic failure Science 2002 298 789 91 10.1126/science.1074069 12399581
Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science. 2002;298:789–91.12399581 10.1126/science.1074069
188. Terry RD Masliah E Salmon DP Butters N DeTeresa R Hill R Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment Ann Neurol 1991 30 572 80 10.1002/ana.410300410 1789684
Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572–80.1789684 10.1002/ana.410300410
189. Herms J Dorostkar MM Dendritic spine pathology in neurodegenerative diseases Annu Rev Pathol 2016 11 221 50 10.1146/annurev-pathol-012615-044216 26907528
Herms J, Dorostkar MM. Dendritic spine pathology in neurodegenerative diseases. Annu Rev Pathol. 2016;11:221–50.26907528 10.1146/annurev-pathol-012615-044216
190. Kumar S Reddy PH The role of synaptic microRNAs in Alzheimer’s disease Biochim Biophys Acta Mol Basis Dis 2020 1866 165937 10.1016/j.bbadis.2020.165937 32827646
Kumar S, Reddy PH. The role of synaptic microRNAs in Alzheimer’s disease. Biochim Biophys Acta Mol Basis Dis. 2020;1866:165937.32827646 10.1016/j.bbadis.2020.165937
191. He Y Wei M Wu Y Qin H Li W Ma X Amyloid β oligomers suppress excitatory transmitter release via presynaptic depletion of phosphatidylinositol-4,5-bisphosphate Nat Commun 2019 10 1193 10.1038/s41467-019-09114-z 30867420
He Y, Wei M, Wu Y, Qin H, Li W, Ma X, et al. Amyloid β oligomers suppress excitatory transmitter release via presynaptic depletion of phosphatidylinositol-4,5-bisphosphate. Nat Commun. 2019;10:1193.30867420 10.1038/s41467-019-09114-z
192. Guo T Noble W Hanger DP Roles of tau protein in health and disease Acta Neuropathol 2017 133 665 704 10.1007/s00401-017-1707-9 28386764
Guo T, Noble W, Hanger DP. Roles of tau protein in health and disease. Acta Neuropathol. 2017;133:665–704.28386764 10.1007/s00401-017-1707-9
193. Morris M Maeda S Vossel K Mucke L The many faces of tau Neuron 2011 70 410 26 10.1016/j.neuron.2011.04.009 21555069
Morris M, Maeda S, Vossel K, Mucke L. The many faces of tau. Neuron. 2011;70:410–26.21555069 10.1016/j.neuron.2011.04.009
194. Markesbery WR Schmitt FA Kryscio RJ Davis DG Smith CD Wekstein DR Neuropathologic substrate of mild cognitive impairment Arch Neurol 2006 63 38 46 10.1001/archneur.63.1.38 16401735
Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, Wekstein DR. Neuropathologic substrate of mild cognitive impairment. Arch Neurol. 2006;63:38–46.16401735 10.1001/archneur.63.1.38
195. Feuillette S Miguel L Frébourg T Campion D Lecourtois M Drosophila models of human tauopathies indicate that Tau protein toxicity in vivo is mediated by soluble cytosolic phosphorylated forms of the protein J Neurochem 2010 113 895 903 10.1111/j.1471-4159.2010.06663.x 20193038
Feuillette S, Miguel L, Frébourg T, Campion D, Lecourtois M. Drosophila models of human tauopathies indicate that Tau protein toxicity in vivo is mediated by soluble cytosolic phosphorylated forms of the protein. J Neurochem. 2010;113:895–903.20193038 10.1111/j.1471-4159.2010.06663.x
196. Bonda DJ Castellani RJ Zhu X Nunomura A Lee HG Perry G A novel perspective on tau in Alzheimer’s disease Curr Alzheimer Res 2011 8 639 42 10.2174/156720511796717131 21605042
Bonda DJ, Castellani RJ, Zhu X, Nunomura A, Lee HG, Perry G, et al. A novel perspective on tau in Alzheimer’s disease. Curr Alzheimer Res. 2011;8:639–42.21605042 10.2174/156720511796717131
197. Mroczko B Groblewska M Litman-Zawadzka A The role of protein misfolding and Tau Oligomers (TauOs) in Alzheimer’s disease (AD) Int J Mol Sci 2019 20 4661 10.3390/ijms20194661 31547024
Mroczko B, Groblewska M, Litman-Zawadzka A. The role of protein misfolding and Tau Oligomers (TauOs) in Alzheimer’s disease (AD). Int J Mol Sci. 2019;20:4661.31547024 10.3390/ijms20194661
198. Gerrits E Brouwer N Kooistra SM Woodbury ME Vermeiren Y Lambourne M Distinct amyloid-β and tau-associated microglia profiles in Alzheimer’s disease Acta Neuropathol 2021 141 681 96 10.1007/s00401-021-02263-w 33609158
Gerrits E, Brouwer N, Kooistra SM, Woodbury ME, Vermeiren Y, Lambourne M, et al. Distinct amyloid-β and tau-associated microglia profiles in Alzheimer’s disease. Acta Neuropathol. 2021;141:681–96.33609158 10.1007/s00401-021-02263-w
199. Azam S Haque ME Kim IS Choi DK Microglial turnover in ageing-related neurodegeneration: therapeutic avenue to intervene in disease progression Cells 2021 10 150 10.3390/cells10010150 33466587
Azam S, Haque ME, Kim IS, Choi DK. Microglial turnover in ageing-related neurodegeneration: therapeutic avenue to intervene in disease progression. Cells. 2021;10:150.33466587 10.3390/cells10010150
200. Park JC Han SH Mook-Jung I Peripheral inflammatory biomarkers in Alzheimer’s disease: a brief review BMB Rep 2020 53 10 19 10.5483/BMBRep.2020.53.1.309 31865964
Park JC, Han SH, Mook-Jung I. Peripheral inflammatory biomarkers in Alzheimer’s disease: a brief review. BMB Rep. 2020;53:10–19.31865964 10.5483/BMBRep.2020.53.1.309
201. Reddy PH Oliver DM Amyloid beta and phosphorylated tau-induced defective autophagy and mitophagy in Alzheimer’s disease Cells 2019 8 488 10.3390/cells8050488 31121890
Reddy PH, Oliver DM. Amyloid beta and phosphorylated tau-induced defective autophagy and mitophagy in Alzheimer’s disease. Cells. 2019;8:488.31121890 10.3390/cells8050488
202. Garcia GC Bartol TM Phan S Bushong EA Perkins G Sejnowski TJ Mitochondrial morphology provides a mechanism for energy buffering at synapses Sci Rep 2019 9 18306 10.1038/s41598-019-54159-1 31797946
Garcia GC, Bartol TM, Phan S, Bushong EA, Perkins G, Sejnowski TJ, et al. Mitochondrial morphology provides a mechanism for energy buffering at synapses. Sci Rep. 2019;9:18306.31797946 10.1038/s41598-019-54159-1
203. Roger AJ Muñoz-Gómez SA Kamikawa R The origin and diversification of mitochondria Curr Biol 2017 27 R1177 r1192 10.1016/j.cub.2017.09.015 29112874
Roger AJ, Muñoz-Gómez SA, Kamikawa R. The origin and diversification of mitochondria. Curr Biol. 2017;27:R1177–r1192.29112874 10.1016/j.cub.2017.09.015
204. Cai Q Tammineni P Alterations in mitochondrial quality control in Alzheimer’s disease Front Cell Neurosci 2016 10 24 10.3389/fncel.2016.00024 26903809
Cai Q, Tammineni P. Alterations in mitochondrial quality control in Alzheimer’s disease. Front Cell Neurosci. 2016;10:24.26903809 10.3389/fncel.2016.00024
205. Oliver D Reddy PH Dynamics of dynamin-related protein 1 in Alzheimer’s disease and other neurodegenerative diseases Cells 2019 8 961 10.3390/cells8090961 31450774
Oliver D, Reddy PH. Dynamics of dynamin-related protein 1 in Alzheimer’s disease and other neurodegenerative diseases. Cells. 2019;8:961.31450774 10.3390/cells8090961
206. Pradeepkiran JA Reddy PH Defective mitophagy in Alzheimer’s disease Ageing Res Rev 2020 64 101191 10.1016/j.arr.2020.101191 33022416
Pradeepkiran JA, Reddy PH. Defective mitophagy in Alzheimer’s disease. Ageing Res Rev. 2020;64:101191.33022416 10.1016/j.arr.2020.101191
207. Bhatti JS Tamarai K Kandimalla R Manczak M Yin X Ramasubramanian B Protective effects of a mitochondria-targeted small peptide SS31 against hyperglycemia-induced mitochondrial abnormalities in the liver tissues of diabetic mice, Tallyho/JngJ mice Mitochondrion 2021 58 49 58 10.1016/j.mito.2021.02.007 33639273
Bhatti JS, Tamarai K, Kandimalla R, Manczak M, Yin X, Ramasubramanian B, et al. Protective effects of a mitochondria-targeted small peptide SS31 against hyperglycemia-induced mitochondrial abnormalities in the liver tissues of diabetic mice, Tallyho/JngJ mice. Mitochondrion. 2021;58:49–58.33639273 10.1016/j.mito.2021.02.007
208. Kren BT Wong PY Sarver A Zhang X Zeng Y Steer CJ MicroRNAs identified in highly purified liver-derived mitochondria may play a role in apoptosis RNA Biol 2009 6 65 72 10.4161/rna.6.1.7534 19106625
Kren BT, Wong PY, Sarver A, Zhang X, Zeng Y, Steer CJ. MicroRNAs identified in highly purified liver-derived mitochondria may play a role in apoptosis. RNA Biol. 2009;6:65–72.19106625 10.4161/rna.6.1.7534
209. Bian Z Li LM Tang R Hou DX Chen X Zhang CY Identification of mouse liver mitochondria-associated miRNAs and their potential biological functions Cell Res 2010 20 1076 8 10.1038/cr.2010.119 20733615
Bian Z, Li LM, Tang R, Hou DX, Chen X, Zhang CY, et al. Identification of mouse liver mitochondria-associated miRNAs and their potential biological functions. Cell Res. 2010;20:1076–8.20733615 10.1038/cr.2010.119
210. Shi Q Gibson GE Up-regulation of the mitochondrial malate dehydrogenase by oxidative stress is mediated by miR-743a J Neurochem 2011 118 440 8 10.1111/j.1471-4159.2011.07333.x 21623795
Shi Q, Gibson GE. Up-regulation of the mitochondrial malate dehydrogenase by oxidative stress is mediated by miR-743a. J Neurochem. 2011;118:440–8.21623795 10.1111/j.1471-4159.2011.07333.x
211. Gao P Tchernyshyov I Chang TC Lee YS Kita K Ochi T c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism Nature 2009 458 762 5 10.1038/nature07823 19219026
Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458:762–5.19219026 10.1038/nature07823
212. Chen Z Li Y Zhang H Huang P Luthra R Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression Oncogene 2010 29 4362 8 10.1038/onc.2010.193 20498629
Chen Z, Li Y, Zhang H, Huang P, Luthra R. Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. Oncogene. 2010;29:4362–8.20498629 10.1038/onc.2010.193
213. Aschrafi A Schwechter AD Mameza MG Natera-Naranjo O Gioio AE Kaplan BB MicroRNA-338 regulates local cytochrome c oxidase IV mRNA levels and oxidative phosphorylation in the axons of sympathetic neurons J Neurosci 2008 28 12581 90 10.1523/JNEUROSCI.3338-08.2008 19020050
Aschrafi A, Schwechter AD, Mameza MG, Natera-Naranjo O, Gioio AE, Kaplan BB. MicroRNA-338 regulates local cytochrome c oxidase IV mRNA levels and oxidative phosphorylation in the axons of sympathetic neurons. J Neurosci. 2008;28:12581–90.19020050 10.1523/JNEUROSCI.3338-08.2008
214. Sarkar S Jun S Rellick S Quintana DD Cavendish JZ Simpkins JW Expression of microRNA-34a in Alzheimer’s disease brain targets genes linked to synaptic plasticity, energy metabolism, and resting state network activity Brain Res 2016 1646 139 51 10.1016/j.brainres.2016.05.026 27235866
Sarkar S, Jun S, Rellick S, Quintana DD, Cavendish JZ, Simpkins JW. Expression of microRNA-34a in Alzheimer’s disease brain targets genes linked to synaptic plasticity, energy metabolism, and resting state network activity. Brain Res. 2016;1646:139–51.27235866 10.1016/j.brainres.2016.05.026
215. Wang J Tang Y Lv X Zhang J Ma B Wen X Corrigendum: “Tectoridin inhibits osteoclastogenesis and bone loss in a murine model of ovariectomy-induced osteoporosis” [Exp. Gerontol. 140: 2020; 111057. DOI:10.1016/j.exger.2020.111057] Exp Gerontol 2023 180 112251 10.1016/j.exger.2023.112251 37487835
Wang J, Tang Y, Lv X, Zhang J, Ma B, Wen X, et al. Corrigendum: “Tectoridin inhibits osteoclastogenesis and bone loss in a murine model of ovariectomy-induced osteoporosis” [Exp. Gerontol. 140: 2020; 111057. DOI:10.1016/j.exger.2020.111057]. Exp Gerontol. 2023;180:112251.37487835 10.1016/j.exger.2023.112251
216. Zhang R Zhou H Jiang L Mao Y Cui X Xie B MiR-195 dependent roles of mitofusin2 in the mitochondrial dysfunction of hippocampal neurons in SAMP8 mice Brain Res 2016 1652 135 43 10.1016/j.brainres.2016.09.047 27693395
Zhang R, Zhou H, Jiang L, Mao Y, Cui X, Xie B, et al. MiR-195 dependent roles of mitofusin2 in the mitochondrial dysfunction of hippocampal neurons in SAMP8 mice. Brain Res. 2016;1652:135–43.27693395 10.1016/j.brainres.2016.09.047
217. Benaroya H Brain energetics, mitochondria, and traumatic brain injury Rev Neurosci 2020 31 363 90 10.1515/revneuro-2019-0086 32004148
Benaroya H. Brain energetics, mitochondria, and traumatic brain injury. Rev Neurosci. 2020;31:363–90.32004148 10.1515/revneuro-2019-0086
218. Silver I Erecińska M Oxygen and ion concentrations in normoxic and hypoxic brain cells Adv Exp Med Biol 1998 454 7 16 10.1007/978-1-4615-4863-8_2 9889871
Silver I, Erecińska M. Oxygen and ion concentrations in normoxic and hypoxic brain cells. Adv Exp Med Biol. 1998;454:7–16.9889871 10.1007/978-1-4615-4863-8_2
219. Kumar S Reddy PH A new discovery of MicroRNA-455-3p in Alzheimer’s disease J Alzheimers Dis 2019 72 S117 s130 10.3233/JAD-190583 31524168
Kumar S, Reddy PH. A new discovery of MicroRNA-455-3p in Alzheimer’s disease. J Alzheimers Dis. 2019;72:S117–s130.31524168 10.3233/JAD-190583
220. Xiong H Chen S Lai L Yang H Xu Y Pang J Modulation of miR-34a/SIRT1 signaling protects cochlear hair cells against oxidative stress and delays age-related hearing loss through coordinated regulation of mitophagy and mitochondrial biogenesis Neurobiol Aging 2019 79 30 42 10.1016/j.neurobiolaging.2019.03.013 31026620
Xiong H, Chen S, Lai L, Yang H, Xu Y, Pang J, et al. Modulation of miR-34a/SIRT1 signaling protects cochlear hair cells against oxidative stress and delays age-related hearing loss through coordinated regulation of mitophagy and mitochondrial biogenesis. Neurobiol Aging. 2019;79:30–42.31026620 10.1016/j.neurobiolaging.2019.03.013
221. Weinberg RB Mufson EJ Counts SE Evidence for a neuroprotective microRNA pathway in amnestic mild cognitive impairment Front Neurosci 2015 9 430 10.3389/fnins.2015.00430 26594146
Weinberg RB, Mufson EJ, Counts SE. Evidence for a neuroprotective microRNA pathway in amnestic mild cognitive impairment. Front Neurosci. 2015;9:430.26594146 10.3389/fnins.2015.00430
222. Tang BL Sirt1 and the mitochondria Mol Cells 2016 39 87 95 10.14348/molcells.2016.2318 26831453
Tang BL. Sirt1 and the mitochondria. Mol Cells. 2016;39:87–95.26831453 10.14348/molcells.2016.2318
223. John A Reddy PH Synaptic basis of Alzheimer’s disease: focus on synaptic amyloid beta, P-tau and mitochondria Ageing Res Rev 2021 65 101208 10.1016/j.arr.2020.101208 33157321
John A, Reddy PH. Synaptic basis of Alzheimer’s disease: focus on synaptic amyloid beta, P-tau and mitochondria. Ageing Res Rev. 2021;65:101208.33157321 10.1016/j.arr.2020.101208
224. Gowda P Reddy PH Kumar S Deregulated mitochondrial microRNAs in Alzheimer’s disease: Focus on synapse and mitochondria Ageing Res Rev 2022 73 101529 10.1016/j.arr.2021.101529 34813976
Gowda P, Reddy PH, Kumar S. Deregulated mitochondrial microRNAs in Alzheimer’s disease: Focus on synapse and mitochondria. Ageing Res Rev. 2022;73:101529.34813976 10.1016/j.arr.2021.101529
225. Remenyi J van den Bosch MW Palygin O Mistry RB McKenzie C Macdonald A miR-132/212 knockout mice reveal roles for these miRNAs in regulating cortical synaptic transmission and plasticity PLoS ONE 2013 8 e62509 10.1371/journal.pone.0062509 23658634
Remenyi J, van den Bosch MW, Palygin O, Mistry RB, McKenzie C, Macdonald A, et al. miR-132/212 knockout mice reveal roles for these miRNAs in regulating cortical synaptic transmission and plasticity. PLoS ONE. 2013;8:e62509.23658634 10.1371/journal.pone.0062509
226. Wingo TS Yang J Fan W Min Canon S Gerasimov ES Lori A Brain microRNAs associated with late-life depressive symptoms are also associated with cognitive trajectory and dementia NPJ Genom Med 2020 5 6 10.1038/s41525-019-0113-8 32047652
Wingo TS, Yang J, Fan W, Min Canon S, Gerasimov ES, Lori A, et al. Brain microRNAs associated with late-life depressive symptoms are also associated with cognitive trajectory and dementia. NPJ Genom Med. 2020;5:6.32047652 10.1038/s41525-019-0113-8
227. Nunomura A Perry G RNA and oxidative stress in Alzheimer’s disease: focus on microRNAs Oxid Med Cell Longev 2020 2020 2638130 10.1155/2020/2638130 33312335
Nunomura A, Perry G. RNA and oxidative stress in Alzheimer’s disease: focus on microRNAs. Oxid Med Cell Longev. 2020;2020:2638130.33312335 10.1155/2020/2638130
228. de Souza/S. Nicolau E Mendes Silva AP Fiaux do Nascimento KK Pereira KS Ribeiro dos Santos G Silva Barroso L P3-085: Interaction network of tau protein, beta-amyloid protein, and amyloid protein precursor under oxidative stress in Alzheimer’s disease Alzheimer’s Dementia 2015 11 P651 P652 10.1016/j.jalz.2015.06.952
de Souza/S. Nicolau E, Mendes Silva AP, Fiaux do Nascimento KK, Pereira KS, Ribeiro dos Santos G, Silva Barroso L, et al. P3-085: Interaction network of tau protein, beta-amyloid protein, and amyloid protein precursor under oxidative stress in Alzheimer’s disease. Alzheimer’s Dementia. 2015;11:P651–P652.10.1016/j.jalz.2015.06.952
229. Calabrese V Lodi R Tonon C D’Agata V Sapienza M Scapagnini G Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich’s ataxia J Neurol Sci 2005 233 145 62 10.1016/j.jns.2005.03.012 15896810
Calabrese V, Lodi R, Tonon C, D’Agata V, Sapienza M, Scapagnini G, et al. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich’s ataxia. J Neurol Sci. 2005;233:145–62.15896810 10.1016/j.jns.2005.03.012
230. Lin YT Seo J Gao F Feldman HM Wen HL Penney J APOE4 causes widespread molecular and cellular alterations associated with Alzheimer’s disease phenotypes in human iPSC-derived brain cell types Neuron 2018 98 1141 1154.e7 10.1016/j.neuron.2018.05.008 29861287
Lin YT, Seo J, Gao F, Feldman HM, Wen HL, Penney J, et al. APOE4 causes widespread molecular and cellular alterations associated with Alzheimer’s disease phenotypes in human iPSC-derived brain cell types. Neuron. 2018;98:1141–1154.e7.29861287 10.1016/j.neuron.2018.05.008
231. Buttini M Orth M Bellosta S Akeefe H Pitas RE Wyss-Coray T Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: isoform-specific effects on neurodegeneration J Neurosci 1999 19 4867 80 10.1523/JNEUROSCI.19-12-04867.1999 10366621
Buttini M, Orth M, Bellosta S, Akeefe H, Pitas RE, Wyss-Coray T, et al. Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: isoform-specific effects on neurodegeneration. J Neurosci. 1999;19:4867–80.10366621 10.1523/JNEUROSCI.19-12-04867.1999
232. Buttini M Masliah E Yu GQ Palop JJ Chang S Bernardo A Cellular source of apolipoprotein E4 determines neuronal susceptibility to excitotoxic injury in transgenic mice Am J Pathol 2010 177 563 9 10.2353/ajpath.2010.090973 20595630
Buttini M, Masliah E, Yu GQ, Palop JJ, Chang S, Bernardo A, et al. Cellular source of apolipoprotein E4 determines neuronal susceptibility to excitotoxic injury in transgenic mice. Am J Pathol. 2010;177:563–9.20595630 10.2353/ajpath.2010.090973
233. Wang C Najm R Xu Q Jeong DE Walker D Balestra ME Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector Nat Med 2018 24 647 57 10.1038/s41591-018-0004-z 29632371
Wang C, Najm R, Xu Q, Jeong DE, Walker D, Balestra ME, et al. Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nat Med. 2018;24:647–57.29632371 10.1038/s41591-018-0004-z
234. Strittmatter WJ Roses AD Apolipoprotein E and Alzheimer’s disease Annu Rev Neurosci 1996 19 53 77 10.1146/annurev.ne.19.030196.000413 8833436
Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer’s disease. Annu Rev Neurosci. 1996;19:53–77.8833436 10.1146/annurev.ne.19.030196.000413
235. Rasmussen KL Tybjærg-Hansen A Nordestgaard BG Frikke-Schmidt R Plasma apolipoprotein E levels and risk of dementia: a Mendelian randomization study of 106,562 individuals Alzheimers Dement 2018 14 71 80 10.1016/j.jalz.2017.05.006 28774656
Rasmussen KL, Tybjærg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. Plasma apolipoprotein E levels and risk of dementia: a Mendelian randomization study of 106,562 individuals. Alzheimers Dement. 2018;14:71–80.28774656 10.1016/j.jalz.2017.05.006
236. Prendecki M Florczak-Wyspianska J Kowalska M Ilkowski J Grzelak T Bialas K APOE genetic variants and apoE, miR-107 and miR-650 levels in Alzheimer’s disease Folia Neuropathol 2019 57 106 16 10.5114/fn.2019.84828 31556571
Prendecki M, Florczak-Wyspianska J, Kowalska M, Ilkowski J, Grzelak T, Bialas K, et al. APOE genetic variants and apoE, miR-107 and miR-650 levels in Alzheimer’s disease. Folia Neuropathol. 2019;57:106–16.31556571 10.5114/fn.2019.84828
237. Cao J Huang M Guo L Zhu L Hou J Zhang L MicroRNA-195 rescues ApoE4-induced cognitive deficits and lysosomal defects in Alzheimer’s disease pathogenesis Mol Psychiatry 2021 26 4687 701 10.1038/s41380-020-0824-3 32632205
Cao J, Huang M, Guo L, Zhu L, Hou J, Zhang L, et al. MicroRNA-195 rescues ApoE4-induced cognitive deficits and lysosomal defects in Alzheimer’s disease pathogenesis. Mol Psychiatry. 2021;26:4687–701.32632205 10.1038/s41380-020-0824-3
238. Zhao L Zhang L Zhu W Chen H Ding Y Cui G Inhibition of microRNA-203 protects against traumatic brain injury induced neural damages via suppressing neuronal apoptosis and dementia-related molecules Physiol Behav 2021 228 113190 10.1016/j.physbeh.2020.113190 33002497
Zhao L, Zhang L, Zhu W, Chen H, Ding Y, Cui G. Inhibition of microRNA-203 protects against traumatic brain injury induced neural damages via suppressing neuronal apoptosis and dementia-related molecules. Physiol Behav. 2021;228:113190.33002497 10.1016/j.physbeh.2020.113190
239. Du Y Yu Y Hu Y Li XW Wei ZX Pan RY Genome-wide, integrative analysis implicates exosome-derived MicroRNA dysregulation in schizophrenia Schizophr Bull 2019 45 1257 66 10.1093/schbul/sby191 30770930
Du Y, Yu Y, Hu Y, Li XW, Wei ZX, Pan RY, et al. Genome-wide, integrative analysis implicates exosome-derived MicroRNA dysregulation in schizophrenia. Schizophr Bull. 2019;45:1257–66.30770930 10.1093/schbul/sby191
240. Chen X Hu Y Cao Z Liu Q Cheng Y Cerebrospinal fluid inflammatory cytokine aberrations in Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis: a systematic review and meta-analysis Front Immunol 2018 9 2122 10.3389/fimmu.2018.02122 30283455
Chen X, Hu Y, Cao Z, Liu Q, Cheng Y. Cerebrospinal fluid inflammatory cytokine aberrations in Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Front Immunol. 2018;9:2122.30283455 10.3389/fimmu.2018.02122
241. Cha DJ Mengel D Mustapic M Liu W Selkoe DJ Kapogiannis D miR-212 and miR-132 are downregulated in neurally derived plasma exosomes of Alzheimer’s patients Front Neurosci 2019 13 1208 10.3389/fnins.2019.01208 31849573
Cha DJ, Mengel D, Mustapic M, Liu W, Selkoe DJ, Kapogiannis D, et al. miR-212 and miR-132 are downregulated in neurally derived plasma exosomes of Alzheimer’s patients. Front Neurosci. 2019;13:1208.31849573 10.3389/fnins.2019.01208
242. Yang TT Liu CG Gao SC Zhang Y Wang PC The serum exosome derived MicroRNA-135a, -193b, and -384 were potential Alzheimer’s disease biomarkers Biomed Environ Sci 2018 31 87 96 29606187
Yang TT, Liu CG, Gao SC, Zhang Y, Wang PC. The serum exosome derived MicroRNA-135a, -193b, and -384 were potential Alzheimer’s disease biomarkers. Biomed Environ Sci. 2018;31:87–96.29606187
243. Liu WL Lin HW Lin MR Yu Y Liu HH Dai YL Emerging blood exosome-based biomarkers for preclinical and clinical Alzheimer’s disease: a meta-analysis and systematic review Neural Regen Res 2022 17 2381 90 10.4103/1673-5374.335832 35535875
Liu WL, Lin HW, Lin MR, Yu Y, Liu HH, Dai YL, et al. Emerging blood exosome-based biomarkers for preclinical and clinical Alzheimer’s disease: a meta-analysis and systematic review. Neural Regen Res. 2022;17:2381–90.35535875 10.4103/1673-5374.335832
244. Walgrave H Balusu S Snoeck S Vanden Eynden E Craessaerts K Thrupp N Restoring miR-132 expression rescues adult hippocampal neurogenesis and memory deficits in Alzheimer’s disease Cell Stem Cell 2021 28 1805 1821.e8 10.1016/j.stem.2021.05.001 34033742
Walgrave H, Balusu S, Snoeck S, Vanden Eynden E, Craessaerts K, Thrupp N, et al. Restoring miR-132 expression rescues adult hippocampal neurogenesis and memory deficits in Alzheimer’s disease. Cell Stem Cell. 2021;28:1805–1821.e8.34033742 10.1016/j.stem.2021.05.001
245. Deng Y Zhang J Sun X Ma G Luo G Miao Z miR-132 improves the cognitive function of rats with Alzheimer’s disease by inhibiting the MAPK1 signal pathway Exp Ther Med 2020 20 159 10.3892/etm.2020.9288 33093897
Deng Y, Zhang J, Sun X, Ma G, Luo G, Miao Z, et al. miR-132 improves the cognitive function of rats with Alzheimer’s disease by inhibiting the MAPK1 signal pathway. Exp Ther Med. 2020;20:159.33093897 10.3892/etm.2020.9288
246. El Fatimy R Li S Chen Z Mushannen T Gongala S Wei Z MicroRNA-132 provides neuroprotection for tauopathies via multiple signaling pathways Acta Neuropathol 2018 136 537 55 10.1007/s00401-018-1880-5 29982852
El Fatimy R, Li S, Chen Z, Mushannen T, Gongala S, Wei Z, et al. MicroRNA-132 provides neuroprotection for tauopathies via multiple signaling pathways. Acta Neuropathol. 2018;136:537–55.29982852 10.1007/s00401-018-1880-5
247. Ramsey SA Liu Z Yao Y Weeder B Combining eQTL and SNP annotation data to identify functional noncoding SNPs in GWAS trait-associated regions Methods Mol Biol 2020 2082 73 86 10.1007/978-1-0716-0026-9_6 31849009
Ramsey SA, Liu Z, Yao Y, Weeder B. Combining eQTL and SNP annotation data to identify functional noncoding SNPs in GWAS trait-associated regions. Methods Mol Biol. 2020;2082:73–86.31849009 10.1007/978-1-0716-0026-9_6
248. Barabási AL Gulbahce N Loscalzo J Network medicine: a network-based approach to human disease Nat Rev Genet 2011 12 56 68 10.1038/nrg2918 21164525
Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12:56–68.21164525 10.1038/nrg2918
249. Soler-López M Zanzoni A Lluís R Stelzl U Aloy P Interactome mapping suggests new mechanistic details underlying Alzheimer’s disease Genome Res 2011 21 364 76 10.1101/gr.114280.110 21163940
Soler-López M, Zanzoni A, Lluís R, Stelzl U, Aloy P. Interactome mapping suggests new mechanistic details underlying Alzheimer’s disease. Genome Res. 2011;21:364–76.21163940 10.1101/gr.114280.110
250. Mostafavi S Gaiteri C Sullivan SE White CC Tasaki S Xu J A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer’s disease Nat Neurosci 2018 21 811 9 10.1038/s41593-018-0154-9 29802388
Mostafavi S, Gaiteri C, Sullivan SE, White CC, Tasaki S, Xu J, et al. A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer’s disease. Nat Neurosci. 2018;21:811–9.29802388 10.1038/s41593-018-0154-9
251. Raj T Shulman JM Keenan BT Chibnik LB Evans DA Bennett DA Alzheimer disease susceptibility loci: evidence for a protein network under natural selection Am J Hum Genet 2012 90 720 6 10.1016/j.ajhg.2012.02.022 22482808
Raj T, Shulman JM, Keenan BT, Chibnik LB, Evans DA, Bennett DA, et al. Alzheimer disease susceptibility loci: evidence for a protein network under natural selection. Am J Hum Genet. 2012;90:720–6.22482808 10.1016/j.ajhg.2012.02.022
252. Yu L Petyuk VA Gaiteri C Mostafavi S Young-Pearse T Shah RC Targeted brain proteomics uncover multiple pathways to Alzheimer’s dementia Ann Neurol 2018 84 78 88 10.1002/ana.25266 29908079
Yu L, Petyuk VA, Gaiteri C, Mostafavi S, Young-Pearse T, Shah RC, et al. Targeted brain proteomics uncover multiple pathways to Alzheimer’s dementia. Ann Neurol. 2018;84:78–88.29908079 10.1002/ana.25266
253. Zhang Q Ma C Gearing M Wang PG Chin LS Li L Integrated proteomics and network analysis identifies protein hubs and network alterations in Alzheimer’s disease Acta Neuropathol Commun 2018 6 19 10.1186/s40478-018-0524-2 29490708
Zhang Q, Ma C, Gearing M, Wang PG, Chin LS, Li L. Integrated proteomics and network analysis identifies protein hubs and network alterations in Alzheimer’s disease. Acta Neuropathol Commun. 2018;6:19.29490708 10.1186/s40478-018-0524-2
254. Picard C Miron J Poirier J Association of TMEM106B with cortical APOE gene expression in neurodegenerative conditions Genes 2024 15 416 10.3390/genes15040416 38674351
Picard C, Miron J, Poirier J. Association of TMEM106B with cortical APOE gene expression in neurodegenerative conditions. Genes. 2024;15:416.38674351 10.3390/genes15040416
255. Piscopo P Albani D Castellano AE Forloni G Confaloni A Frontotemporal lobar degeneration and MicroRNAs Front Aging Neurosci 2016 8 17 10.3389/fnagi.2016.00017 26903860
Piscopo P, Albani D, Castellano AE, Forloni G, Confaloni A. Frontotemporal lobar degeneration and MicroRNAs. Front Aging Neurosci. 2016;8:17.26903860 10.3389/fnagi.2016.00017
256. Chen-Plotkin AS Unger TL Gallagher MD Bill E Kwong LK Volpicelli-Daley L TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways J Neurosci 2012 32 11213 27 10.1523/JNEUROSCI.0521-12.2012 22895706
Chen-Plotkin AS, Unger TL, Gallagher MD, Bill E, Kwong LK, Volpicelli-Daley L, et al. TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. J Neurosci. 2012;32:11213–27.22895706 10.1523/JNEUROSCI.0521-12.2012
